

2-{3-[2-(4-flurophenyl)oxazole-4-yl methoxy]phenoxymethyl}-6-methylbenzoic acid

Hong,

Both Chemical Abstracts & Chem Draw think this is the structure of the elected species. Note difference between this & applicants' drawing in claim 94. ☺ Search allowed for either structure.

Barb

THIS PAGE BLANK (USPTO)

```
=> fil reg; d stat que l25; fil capl; d que nos l26; fil uspatf; d que nos l29
FILE 'REGISTRY' ENTERED AT 16:59:34 ON 28 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 OCT 2002  HIGHEST RN 466637-52-5
DICTIONARY FILE UPDATES:  27 OCT 2002  HIGHEST RN 466637-52-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf


L18          620 SEA FILE=REGISTRY ABB=ON  (100-83-4/BI OR 1008-88-4/BI OR
                 1011-50-3/BI OR 102-47-6/BI OR 103-74-2/BI OR 10340-77-9/BI OR
                 103788-61-0/BI OR 103788-64-3/BI OR 103788-65-4/BI OR 104-83-6/
                 BI OR 104-90-5/BI OR 10447-76-4/BI OR 105-36-2/BI OR 105983-77-
                 5/BI OR 106435-53-4/BI OR 107432-15-5/BI OR 1078-28-0/BI OR
                 107813-58-1/BI OR 108-46-3/BI OR 108325-70-8/BI OR 1122-56-1/BI
                  OR 1123-63-3/BI OR 1128-61-6/BI OR 118-48-9/BI OR 118-75-2/BI
                 OR 119-36-8/BI OR 120-50-3/BI OR 120-72-9/BI OR 1201-68-9/BI
                 OR 120128-20-3/BI OR 123225-57-0/BI OR 123225-58-1/BI OR
                 123225-59-2/BI OR 123225-60-5/BI OR 123225-64-9/BI OR 123225-66
                 -1/BI OR 123225-67-2/BI OR 123225-69-4/BI OR 123225-71-8/BI OR
                 123225-73-0/BI OR 123225-75-2/BI OR 123225-76-3/BI OR 123225-78
                 -5/BI OR 123225-80-9/BI OR 123225-81-0/BI OR 123225-82-1/BI OR
                 123225-94-5/BI OR 123225-95-6/BI OR 123225-96-7/BI OR 123225-97
                 -8/BI OR 123225-98-9/BI OR 123225-99-0/BI OR 123226-00-6/BI OR
                 123226-01-7/BI OR 123226-03-9/BI OR 123226-04-0/BI OR 123226-05
                 -1/BI OR 123226-07-3/BI OR 123226-08-4/BI OR 123226-09-5/BI OR
                 123226-11-9/BI OR 123226-13-1/BI OR 123226-14-2/BI OR 123226-15
                 -3/BI OR 123226-16-4/BI OR 123226-17-5/BI OR 123226-18-6/BI OR
                 123226-19-7/BI OR 123226-20-0/BI OR 123226-21-1/BI OR 123226-22
                 -2/BI OR 123226-23-3/BI OR 123226-24-4/BI OR 123226-25-5/BI OR
                 123226-26-6/BI OR 123226-27-7/BI OR 123226-28-8/BI OR 123226-29
                 -9/BI OR 123247-23-4/BI OR 123247-24-5/BI OR 123247-25-6/BI OR
                 123247-27-8/BI OR 123247-28-9/BI OR 123692-25-1/BI OR 123692-28
                 -4/BI OR 123692-29-5/BI OR 123692-36-4/BI OR 123692-37-5/BI OR
                 123692-38-6/BI OR 123692-39-7/BI OR 123692-40-0/BI OR 123715-60
                 -6/BI OR 123791-11-7/BI OR 123791-12-8/BI OR 123791-15-1/BI OR
                 123791-16-2/BI OR 123791-17-3/BI OR 123791-18-4/BI OR 124993-46
                 -0/BI OR 128760-03-2/BI OR 128760-38-3/BI OR 128760
L22                  STR

Cy-G1-Cy-G1-Cy
1  2  3  4  5

REP G1=(0-11) A
NODE ATTRIBUTES:
CONNECT IS M2  RC AT   5
DEFAULT MLEVEL IS ATOM
```

since the first claim was so broad (couldn't get structure to run, even with limitations in claims 31-34), I selected the Registry #'s from the inventors' own work & searched this structure against that set (includes elected species)

Cy = any cyclic group
A = any non-hydrogen atom

Searched by Barb O'Bryen, STIC 308-4291

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE
L25 389 SEA FILE=REGISTRY SUB=L18 SSS FUL L22

100.0% PROCESSED 619 ITERATIONS 389 ANSWERS
SEARCH TIME: 00.00.03

FILE 'CAPLUS' ENTERED AT 16:59:34 ON 28 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Oct 2002 VOL 137 ISS 18
FILE LAST UPDATED: 27 Oct 2002 (20021027/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L18 620 SEA FILE=REGISTRY ABB=ON (100-83-4/BI OR 1008-88-4/BI OR 1011-50-3/BI OR 102-47-6/BI OR 103-74-2/BI OR 10340-77-9/BI OR 103788-61-0/BI OR 103788-64-3/BI OR 103788-65-4/BI OR 104-83-6/BI OR 104-90-5/BI OR 10447-76-4/BI OR 105-36-2/BI OR 105983-77-5/BI OR 106435-53-4/BI OR 107432-15-5/BI OR 1078-28-0/BI OR 107813-58-1/BI OR 108-46-3/BI OR 108325-70-8/BI OR 1122-56-1/BI OR 1123-63-3/BI OR 1128-61-6/BI OR 118-48-9/BI OR 118-75-2/BI OR 119-36-8/BI OR 120-50-3/BI OR 120-72-9/BI OR 1201-68-9/BI OR 120128-20-3/BI OR 123225-57-0/BI OR 123225-58-1/BI OR 123225-59-2/BI OR 123225-60-5/BI OR 123225-64-9/BI OR 123225-66-1/BI OR 123225-67-2/BI OR 123225-69-4/BI OR 123225-71-8/BI OR 123225-73-0/BI OR 123225-75-2/BI OR 123225-76-3/BI OR 123225-78-5/BI OR 123225-80-9/BI OR 123225-81-0/BI OR 123225-82-1/BI OR 123225-94-5/BI OR 123225-95-6/BI OR 123225-96-7/BI OR 123225-97-8/BI OR 123225-98-9/BI OR 123225-99-0/BI OR 123226-00-6/BI OR 123226-01-7/BI OR 123226-03-9/BI OR 123226-04-0/BI OR 123226-05-1/BI OR 123226-07-3/BI OR 123226-08-4/BI OR 123226-09-5/BI OR 123226-11-9/BI OR 123226-13-1/BI OR 123226-14-2/BI OR 123226-15-3/BI OR 123226-16-4/BI OR 123226-17-5/BI OR 123226-18-6/BI OR 123226-19-7/BI OR 123226-20-0/BI OR 123226-21-1/BI OR 123226-22

-2/BI OR 123226-23-3/BI OR 123226-24-4/BI OR 123226-25-5/BI OR 123226-26-6/BI OR 123226-27-7/BI OR 123226-28-8/BI OR 123226-29-9/BI OR 123247-23-4/BI OR 123247-24-5/BI OR 123247-25-6/BI OR 123247-27-8/BI OR 123247-28-9/BI OR 123692-25-1/BI OR 123692-28-4/BI OR 123692-29-5/BI OR 123692-36-4/BI OR 123692-37-5/BI OR 123692-38-6/BI OR 123692-39-7/BI OR 123692-40-0/BI OR 123715-60-6/BI OR 123791-11-7/BI OR 123791-12-8/BI OR 123791-15-1/BI OR 123791-16-2/BI OR 123791-17-3/BI OR 123791-18-4/BI OR 124993-46-0/BI OR 128760-03-2/BI OR 128760-38-3/BI OR 128760

L22 STR

L25 389 SEA FILE=REGISTRY SUB=L18 SSS FUL L22

L26 28 SEA FILE=CAPLUS ABB=ON L25

FILE 'USPATFULL' ENTERED AT 16:59:34 ON 28 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Oct 2002 (20021024/PD)
FILE LAST UPDATED: 24 Oct 2002 (20021024/ED)
HIGHEST GRANTED PATENT NUMBER: US6470498
HIGHEST APPLICATION PUBLICATION NUMBER: US2002157162
CA INDEXING IS CURRENT THROUGH 24 Oct 2002 (20021024/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Oct 2002 (20021024/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L18 620 SEA FILE=REGISTRY ABB=ON (100-83-4/BI OR 1008-88-4/BI OR 1011-50-3/BI OR 102-47-6/BI OR 103-74-2/BI OR 10340-77-9/BI OR 103788-61-0/BI OR 103788-64-3/BI OR 103788-65-4/BI OR 104-83-6/BI OR 104-90-5/BI OR 10447-76-4/BI OR 105-36-2/BI OR 105983-77-5/BI OR 106435-53-4/BI OR 107432-15-5/BI OR 1078-28-0/BI OR 107813-58-1/BI OR 108-46-3/BI OR 108325-70-8/BI OR 1122-56-1/BI OR 1123-63-3/BI OR 1128-61-6/BI OR 118-48-9/BI OR 118-75-2/BI OR 119-36-8/BI OR 120-50-3/BI OR 120-72-9/BI OR 1201-68-9/BI OR 120128-20-3/BI OR 123225-57-0/BI OR 123225-58-1/BI OR 123225-59-2/BI OR 123225-60-5/BI OR 123225-64-9/BI OR 123225-66-1/BI OR 123225-67-2/BI OR 123225-69-4/BI OR 123225-71-8/BI OR 123225-73-0/BI OR 123225-75-2/BI OR 123225-76-3/BI OR 123225-78

-5/BI OR 123225-80-9/BI OR 123225-81-0/BI OR 123225-82-1/BI OR
123225-94-5/BI OR 123225-95-6/BI OR 123225-96-7/BI OR 123225-97
-8/BI OR 123225-98-9/BI OR 123225-99-0/BI OR 123226-00-6/BI OR
123226-01-7/BI OR 123226-03-9/BI OR 123226-04-0/BI OR 123226-05
-1/BI OR 123226-07-3/BI OR 123226-08-4/BI OR 123226-09-5/BI OR
123226-11-9/BI OR 123226-13-1/BI OR 123226-14-2/BI OR 123226-15
-3/BI OR 123226-16-4/BI OR 123226-17-5/BI OR 123226-18-6/BI OR
123226-19-7/BI OR 123226-20-0/BI OR 123226-21-1/BI OR 123226-22
-2/BI OR 123226-23-3/BI OR 123226-24-4/BI OR 123226-25-5/BI OR
123226-26-6/BI OR 123226-27-7/BI OR 123226-28-8/BI OR 123226-29
-9/BI OR 123247-23-4/BI OR 123247-24-5/BI OR 123247-25-6/BI OR
123247-27-8/BI OR 123247-28-9/BI OR 123692-25-1/BI OR 123692-28
-4/BI OR 123692-29-5/BI OR 123692-36-4/BI OR 123692-37-5/BI OR
123692-38-6/BI OR 123692-39-7/BI OR 123692-40-0/BI OR 123715-60
-6/BI OR 123791-11-7/BI OR 123791-12-8/BI OR 123791-15-1/BI OR
123791-16-2/BI OR 123791-17-3/BI OR 123791-18-4/BI OR 124993-46
-0/BI OR 128760-03-2/BI OR 128760-38-3/BI OR 128760

L22 STR
L25 389 SEA FILE=REGISTRY SUB=L18 SSS FUL L22
L29 13 SEA FILE=USPATFULL ABB=ON L25

=> dup rem l26, l29

FILE 'CAPLUS' ENTERED AT 16:59:42 ON 28 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:59:42 ON 28 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L26
PROCESSING COMPLETED FOR L29
L31 38 DUP REM L26 L29 (3 DUPLICATES REMOVED)
ANSWERS '1-28' FROM FILE CAPLUS
ANSWERS '29-38' FROM FILE USPATFULL

=> d ibib abs hitstr l31 1-38; fil cao; d que nos l30; fil hom

L31 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 1992:235459 CAPLUS
DOCUMENT NUMBER: 116:235459
TITLE: Preparation of [(quinolylmethoxy)benzyloxy]chromenonec
arboxylates and analogs as leukotriene antagonists
INVENTOR(S): Huang, Fu Chich; Campbell, Henry F.; Learn, Keith S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 20 pp. Cont.-in-part of U.S. 4,977,162.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5082849	A	19920121	US 1991-659403	19910308
US 4977162	A	19901211	US 1989-379528	19890713
WO 9101123	A2	19910207	WO 1990-US3847	19900709
WO 9101123	A3	19910307		

W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE

PRIORITY APPLN. INFO.: US 1989-379528 19890713
WO 1990-US3847 19900709
OTHER SOURCE(S): MARPAT 116:235459

GI



AB Title compds. [I; R2 = H, (CRR1)eD(CRR1)fEZ; vicinal R2 may form band; geminal R2 may form O; R = H, (CH2)xM(CH2)yX; D = O, S, NR1, CR1:CR1; E = bond, CR1:CR1; M = band, O, S, NR1, CR1:CR1; R1 = H, (ar)alkyl; R5 = R7 (CR1R1)aA(CR1R1)bZ1(CR1R1)cB(CR1R1)d; A = bond, O, S, CR1:CR1; B = bond, O, SO0-2, NR, CO, etc.; R6 = H, OH, alkoxy, halo, haloalkyl, etc.; R7 = (substituted) quinolyl; X = H, (cyclo)alkyl, aryl, acyl, alkoxy, etc.; Z = cyano, CO2R1, tetrazolyl, etc.; Z1 = (substituted) phenylenediyl; a, b = 0, 1; c-f, x, y = 0-3] were prepd. Thus, 2,4-(HO)2C6H3COMe was cyclocondensed with (CO2Et)2 and the product treated, in turn, with NH3 and POCl3 to give chromenone II (R2 = cyano, R5 = OH) which was condensed with 2-[(3-chloromethylphenoxy)methyl]quinoline (prepn. given) to give, after cyclocondensation with NaN3, II [R2 = 5-tetrazolyl, R5 = 3-(R7CH2O)C6H4CH2O, R7 = 2-quinolyl].

IT **133628-51-0P 134138-98-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as leukotriene antagonist)

RN 133628-51-0 CAPLUS

CN 2H-1-Benzopyran-2-propanoic acid, 3,4-dihydro-2-methyl-4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 134138-98-0 CAPLUS

CN 4H-1-Benzopyran-2-carboxylic acid, 4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L31 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
ACCESSION NUMBER: 1991:408594 CAPLUS
DOCUMENT NUMBER: 115:8594

TITLE: Preparation of quinolinylchromone derivatives for treatment of hypersensitive ailments
INVENTOR(S): Huang, Fu Chih; Campbell, Henry F.; Learn, Keith S.; Galemmo, Robert A., Jr.
PATENT ASSIGNEE(S): Rorer Pharmaceutical Corp., USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4977162	A	19901211	US 1989-379528	19890713
CA 2036381	AA	19910114	CA 1990-2036381	19900709
WO 9101123	A2	19910207	WO 1990-US3847	19900709
WO 9101123	A3	19910307		
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9061605	A1	19910222	AU 1990-61605	19900709
AU 636087	B2	19930408		
EP 434827	A1	19910703	EP 1990-912046	19900709
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04501430	T2	19920312	JP 1990-511282	19900709
JP 07121940	B4	19951225		
US 5082849	A	19920121	US 1991-659403	19910308

PRIORITY APPLN. INFO.: US 1989-379528 19890713
WO 1990-US3847 19900709
OTHER SOURCE(S): MARPAT 115:8594
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = O, S, bond, (substituted) vinylene; B = bond, O, S, SO, SO2, (substituted) imino, etc.; D = O, S, (substituted) imino, vinylene bond; E = bond, (substituted) vinylene; a, b = 0, 1; c, d, e, f = 0-3; n = 0-2; R = H (substituted) alkyl contg. optional hetero atom, etc., R1 = H, C1-6 alkyl, PhCH2, phenethyl; R2 = H, R2R2 = bond; R3 = H, C1-6 alkyl, alkoxy, OH, etc.; R4 = H, OH, C2-6 alkoxy, etc., Z = cyano, CO2R1, tetrazolyl, etc.], useful as lipoxygenase inhibitors and/or leukotriene antagonists having antiinflammatory and antiallergic properties, are prepd. To a suspension of phosphonium salt II (prepn. given) in DMF was added 80% NaH in oil dispersion with stirring at 0.degree. and a soln. of aldehyde III in DMF was added with stirring to give the vinylene compd. (E)-IV (R5 = cyano), which (0.90 g) was heated with NH4Cl and NaN3 at 100.degree. to give 0.7 g (E)-IV (R5 = 5-tetrazolyl) (V). V was hydrogenated over 10% Pd-C to give the ethylene deriv. Also prepd. were over 50 addnl. I and intermediates. Slow-reacting substance of anaphylaxis binding assay and LTD4 binding assay were given.

IT **133628-51-0P 134138-98-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergic and antiinflammatory agent)

RN 133628-51-0 CAPLUS

CN 2H-1-Benzopyran-2-propanoic acid, 3,4-dihydro-2-methyl-4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 134138-98-0 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L31 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
ACCESSION NUMBER: 1992:106117 CAPLUS
DOCUMENT NUMBER: 116:106117
TITLE: Preparation of quinoline derivatives as inflammation and allergy inhibitors
INVENTOR(S): Huang, Fuchi; Galemmo, Robert A., Jr.; Campbell, Henry F.
PATENT ASSIGNEE(S): Rorer Pharmaceutical Corp., USA
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 116,420.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4920131	A	19900424	US 1988-209428	19880621
US 4920132	A	19900424	US 1987-116420	19871103
US 4920133	A	19900424	US 1987-116428	19871103
US 4920130	A	19900424	US 1987-116597	19871103
AU 8927946	A1	19890601	AU 1989-27946	19881101
AU 633475	B2	19930204		
JP 03500889	T2	19910228	JP 1989-500520	19881101
JP 07107053	B4	19951115		
EP 348155	A1	19891227	EP 1989-306232	19890620
EP 348155	B1	19990512		
R: DE, ES, FR, GB, IT				
WO 8912628	A1	19891228	WO 1989-US2691	19890620
W: JP, US				
EP 784052	A1	19970716	EP 1997-200638	19890620
R: DE, ES, FR, GB, IT				
ES 2134755	T3	19991016	ES 1989-306232	19890620
US 5059610	A	19911022	US 1990-477896	19900420
US 5166210	A	19921124	US 1991-724745	19910702

PRIORITY APPLN. INFO.: US 1987-116420 19871103
US 1987-116428 19871103

US 1987-116597 19871103
US 1988-209428 19880621
WO 1988-US3897 19881101
EP 1989-306232 19890620
US 1990-499513 19900420
OTHER SOURCE(S): CASREACT 116:106117; MARPAT 116:106117

GI



I



II



AB The title compds. I [A = O, S; Q = Q1; B = bond, O, S, SO, SO2, etc.; D = O, S, etc.; E = bond, CR1:CR1; a = 0-2; b = 0,1,; c = 0-4; d = 0-5; e = 0-4; f = 0-5; n = 0-2; R' = H, C1-6 alkyl, OH, C1-6 alkoxy, CO2H, etc.; R'' = H, OH, C1-6 alkoxy, halo, CF3, etc.; R1 = H, C1-6 alkyl, PhCH2, phenethyl; R = (CH2)xX, S(CH2)xX, etc.; X = H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, etc.; x = 0-3; Z = CO2R1, cyano, CONHSO2R3; R3 = H, C1-6 alkyl, CF3, Ph, PhCH2] were prepd. I are antagonists of leukotriene D4 and are useful as inflammation and allergy inhibitors (no data). Reaction of 3-(quinolin-2-yl)methoxyphenol with Et 2-(2-bromomethylphenoxy)propionate in the presence of K2CO3, followed by sapon. and workup, gave quinoline II.

IT **120128-20-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn of, as inflammation and allergy inhibitor)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:594844 CAPLUS
DOCUMENT NUMBER: 137:140518
TITLE: Preparation of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid amide derivatives as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Marfat, Anthony; McKechney, Michael William
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060898	A1	20020808	WO 2001-IB2728	20011224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002123520	A1	20020905	US 2002-62145	20020131

PRIORITY APPLN. INFO.: US 2001-265486P P 20010131
OTHER SOURCE(S): MARPAT 137:140518
GI



I



II

AB Title compds. I [wherein p = 0-1; q = 0-1; provided that when q = 0, n =

2; m = 0-3; n = 1-2; W1 and W2 = independently O, SO0-2, or NR3; or W2 = (un)substituted methylene; Y = SO0-2, O, NO0-1, NR3, or (un)substituted methylene; ; RA and RB = independently H, F, CF3, alkyl, or (un)substituted cycloalkyl, Ph, or benzyl; or when m = 1, CRARB = (un)substituted spiro; RC and RD have the same meaning as RA and RB except that one of them must be H; R1 and R2 = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, alkoxy, phenoxy, carbamoyl, etc.; R3 = H, alkyl, Ph, benzyl, alkoxy, phenoxy, etc.; R4, R5, and R6 = H, F, Cl, and (un)substituted (cyclo)alkyl, alkenyl, alkynyl, Ph, benzyl, pyridyl, alkoxy, phenoxy, acyl, carboxy, CN, NO2, carbamoyl, ureido, (hetero)aryl, etc.; G1 and G2 = independently (un)satd. carbocyclyl or heterocyclyl; E = (un)substituted carboxy, carbamoyl, acyl, hydroxyalkyl, cyanoalkyl, acylamino, ureido, amino, heterocyclyl, etc.] were prepd. as inhibitors of PDE4 (no data). For example, 4-(3-cyanophenoxy)thiazole-5-carboxylic acid was treated with 2-(4-aminomethylphenyl)propan-2-ol in the presence of EDCl and HOBT in DMF to give the thiazolamide II. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

IT **120128-20-3**, RG-12525
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with PDE4 inhibitors; prepn. of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid amide derivs. as inhibitors of PDE4 isoenzymes)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:594842 CAPLUS
DOCUMENT NUMBER: 137:154859
TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-IB2726	20011224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-265304P P 20010131
OTHER SOURCE(S): MARPAT 137:154859
GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-

ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

IT **120128-20-3**, RG-12525
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with PDE4 inhibitors; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:594822 CAPLUS
DOCUMENT NUMBER: 137:154857
TITLE: Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Productors Inc., USA
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060875	A1	20020808	WO 2001-IB2341	20011206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-265492P P 20010131
OTHER SOURCE(S): MARPAT 137:154857
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = 0, SOt (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOk (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety], useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepd. E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzeneboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001 .mu.M to 20.0 .mu.M in whole blood assay for LTE4.

IT **120128-20-3**, RG-12525
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with; prepn. of biaryl nicotinamides as inhibitors of PDE4 isoenzymes)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:591707 CAPLUS
DOCUMENT NUMBER: 137:140509
TITLE: Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1229034	A1	20020807	EP 2002-250202	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002111495	A1	20020815	US 2002-62811	20020131

PRIORITY APPLN. INFO.: US 2001-265240P P 20010131
US 1997-43403P P 19970404
US 1998-105120P P 19981021
OTHER SOURCE(S): MARPAT 137:140509

GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

IT **120128-20-3**, RG-12525
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:676588 CAPLUS
DOCUMENT NUMBER: 135:221312
TITLE: Therapeutic uses of PPAR mediators as ABC-1 expression modulators, and preparation thereof
INVENTOR(S): Jaye, Michael; Duverger, Nicolas; Searfoss, George; Minnich, Anne
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066098	A2	20010913	WO 2001-EP2482	20010306
WO 2001066098	A3	20020404		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-188323P P 20000309
GB 2000-13589 A 20000602

OTHER SOURCE(S): MARPAT 135:221312

AB The invention discloses the use of PPAR mediators, and their pharmaceutical compns., as ATP binding cassette transporter 1 (ABC-1) expression modulators, wherein the PPAR ligand receptor agonists of the invention are useful as inducers of ABC-1 expression. Prepn. of compds. of the invention is included. Also disclosed are methods for treating e.g. low levels of HDL.

IT **120128-20-3P 123225-57-0P 123225-58-1P**
123225-59-2P 123225-60-5P 123225-64-9P
123225-66-1P 123225-67-2P 123225-69-4P
123225-71-8P 123225-73-0P 123225-75-2P
123225-76-3P 123225-78-5P 123225-80-9P
123225-81-0P 123225-82-1P 123225-94-5P
123225-95-6P 123225-96-7P 123225-97-8P
123225-98-9P 123225-99-0P 123226-00-6P
123226-01-7P 123226-03-9P 123226-04-0P
123226-05-1P 123226-07-3P 123226-08-4P
123226-09-5P 123226-11-9P 123226-13-1P
123226-14-2P 123226-15-3P 123226-16-4P
123226-17-5P 123226-18-6P 123226-19-7P
123226-20-0P 123226-21-1P 123226-22-2P
123226-23-3P 123226-24-4P 123226-25-5P
123226-26-6P 123226-27-7P 123247-23-4P
123247-24-5P 123247-25-6P 123247-27-8P
123247-28-9P 123692-25-1P 123692-29-5P
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
123791-11-7P 123791-12-8P 123791-15-1P
123791-16-2P 123791-17-3P 123791-18-4P
124993-46-0P 128760-03-2P 128760-51-0P
128760-53-2P 128760-54-3P 128760-55-4P
128760-56-5P 128760-57-6P 128760-59-8P
128760-60-1P 128760-61-2P 128760-62-3P
128760-69-0P 128760-73-6P 128760-74-7P
128760-75-8P 133628-51-0P 133628-56-5P
134138-98-0P 223771-70-8P 223771-76-4P
223771-79-7P 223771-81-1P 223772-08-5P
223772-12-1P 223772-14-3P 223772-15-4P
223772-18-7P 223772-26-7P 223772-42-7P
223772-43-8P 223772-45-0P 223772-46-1P
303216-78-6P 303216-82-2P 303216-91-3P
303216-94-6P 303216-98-0P 303217-06-3P
303217-08-5P 303217-10-9P 303217-12-1P
303217-15-4P 303217-18-7P 303217-21-2P
303217-27-8P 303217-33-6P 303217-46-1P
303217-48-3P 303217-76-7P 303217-81-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR mediators as ABC-1 expression modulators, prepn., and therapeutic use)

RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-57-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-58-1 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-59-2 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-60-5 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-64-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-66-1 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-67-2 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-69-4 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-71-8 CAPLUS
CN Benzoic acid, 3-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl

]- (9CI) (CA INDEX NAME)



RN 123225-73-0 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-3-(1H-tetrazol-5-ylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-75-2 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-76-3 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-78-5 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-80-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-81-0 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-82-1 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-94-5 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-95-6 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-96-7 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-97-8 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-98-9 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-99-0 CAPLUS
CN Acetic acid, [4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-00-6 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123226-01-7 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-03-9 CAPLUS
CN Propanoic acid, 2-[2-[[4-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-04-0 CAPLUS
CN Acetic acid, [2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-05-1 CAPLUS
CN Acetic acid, [3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-07-3 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-08-4 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-09-5 CAPLUS
CN Pentanedioic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-11-9 CAPLUS
CN Pentanoic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-13-1 CAPLUS
CN Pentanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-14-2 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[4-(2-quinolinylmethoxy)phenoxy]methyl
]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-15-3 CAPLUS
CN Propanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-16-4 CAPLUS
CN Pentanedioic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-17-5 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-18-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-19-7 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-20-0 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-21-1 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-22-2 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-23-3 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-24-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-25-5 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-26-6 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-
quinolinylmethoxy)phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl

RN 123226-27-7 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]-
(9CI) (CA INDEX NAME)



RN 123247-23-4 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methy

l]- (9CI) (CA INDEX NAME)



RN 123247-24-5 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 123247-25-6 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-27-8 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123247-28-9 CAPLUS
CN Acetic acid, [6-acetyl-2-propyl-3-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 123692-25-1 CAPLUS

CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 CAPLUS
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]-

(9CI) (CA INDEX NAME)



RN 123692-40-0 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-11-7 CAPLUS
CN Quinoline, 2-[[4-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-12-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 123791-15-1 CAPLUS

CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-16-2 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 123791-17-3 CAPLUS
CN Quinoline, 2-[[3-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-18-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 124993-46-0 CAPLUS
CN Quinoline, 2-[2-[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 128760-03-2 CAPLUS
CN Propanoic acid, 2-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 128760-51-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[4-(2-
quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-53-2 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-54-3 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-55-4 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 128760-56-5 CAPLUS
CN Acetamide, 2-[4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-57-6 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 128760-59-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-60-1 CAPLUS
CN Propanoic acid, 2-[2-propyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 128760-61-2 CAPLUS
CN Acetic acid, [4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-62-3 CAPLUS
CN Acetic acid, [4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-69-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-73-6 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-74-7 CAPLUS
CN Quinoline, 8-fluoro-2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-75-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 133628-51-0 CAPLUS
CN 2H-1-Benzopyran-2-propanoic acid, 3,4-dihydro-2-methyl-4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 133628-56-5 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 6-chloro-4-oxo-5-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 134138-98-0 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 223771-70-8 CAPLUS
CN Acetic acid, [2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223771-76-4 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-79-7 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-81-1 CAPLUS
CN Acetic acid, [2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-08-5 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-12-1 CAPLUS
CN Benzeneacetic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-14-3 CAPLUS

CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-15-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 223772-18-7 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-26-7 CAPLUS
CN Acetic acid, [2-methyl-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-42-7 CAPLUS
CN Propanoic acid, 2-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-43-8 CAPLUS
CN Benzeneacetic acid, 2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-45-0 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303216-78-6 CAPLUS
CN Quinoline, 2-[[[1-methyl-3-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-82-2 CAPLUS
CN Quinoline, 2-[[[1-methyl-3-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-91-3 CAPLUS
CN Quinoline, 2-[[[1-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-94-6 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303216-98-0 CAPLUS
CN Quinoline, 2-[[[1-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-06-3 CAPLUS
CN 3-Furancarboxylic acid, 2-methyl-5-[4-(2-quinolinylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303217-08-5 CAPLUS
CN 3-Furancarboxylic acid, 2-methyl-5-[4-(2-quinolinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 303217-10-9 CAPLUS
CN Quinoline, 2-[[[5,6,7,8-tetrahydro-7-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-2-naphthalenyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-12-1 CAPLUS
CN 1H-Indole-3-carboxylic acid, 1-methyl-5-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303217-15-4 CAPLUS
CN Benzamide, 3-[[1,2,3,4-tetrahydro-7-(2-quinolinylmethoxy)-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-18-7 CAPLUS
CN Benzoic acid, 3-[[1,2,3,4-tetrahydro-7-(2-quinolinylmethoxy)-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-21-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-(2-quinolinylmethoxy)-2-[[3-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-27-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 303217-33-6 CAPLUS
CN Propanoic acid, 2-[2-[[4-[2-(7-chloro-2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-46-1 CAPLUS
CN Quinoline, 2-[(1E)-2-[4-[(1E)-2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 303217-48-3 CAPLUS
CN Quinoline, 2-[(1E)-2-[4-[(1Z)-2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 303217-76-7 CAPLUS
CN Acetic acid, [3-[2-oxo-2-[3-(2-quinolinylmethoxy)phenyl]-1-(2-quinolinylmethyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-81-4 CAPLUS
CN Benzenepropanoic acid, 2-[[3-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-.alpha.-propyl- (9CI) (CA INDEX NAME)



IT **303217-99-4 303220-49-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PPAR mediators as ABC-1 expression modulators, prepn., and therapeutic use)
RN 303217-99-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-49-7 CAPLUS
CN Benzoic acid, 2-methyl-4-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



L31 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:160765 CAPLUS
DOCUMENT NUMBER: 135:162060
TITLE: Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-.gamma. agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity
AUTHOR(S): Fayer, Jessica L.; Zannikos, Peter N.; Stevens, Jeffrey C.; Luo, Yongqi; Sidhu, Rajinder; Kirkesseli, Stephane
CORPORATE SOURCE: Departments of Drug Metabolism and Pharmacokinetics, Collegeville, PA, USA
SOURCE: Journal of Clinical Pharmacology (2001), 41(3), 305-316
CODEN: JCPCBR; ISSN: 0091-2700
PUBLISHER: Sage Publications
DOCUMENT TYPE: Journal
LANGUAGE: English
AB RG 12525 (2-[[4-[[2-(1H-tetrazole-5-ylmethyl)phenyl]methoxy]phenoxy]methyl

] quinolone) is a novel peroxisome proliferator-activated receptor gamma (PPAR-.gamma.) agonist. In vitro microsomal inhibition assays indicated that RG 12525 is a potent inhibitor of CYP3A4, with a Ki value of 0.5 .mu.M. With the conservative assumption that the total plasma concn. of drug was available to metabolic enzymes following RG 12525 oral administration, marked inhibition of CYP3A4 was expected to substantially reduce the systemic clearance of compds. metabolized by this enzyme. The possibility also existed for inhibition of intestinal and hepatic CYP3A4 by RG 12525 to reduce "first-pass" metab. and increase abs. bioavailability of CYP3A4 substrates orally coadministered. Consequently, an in vivo drug-drug interaction study was performed to evaluate the effects of orally administered RG 12525 on in vivo CYP3A4 activity in healthy male subjects. The pharmacokinetics of oral midazolam, a probe for intestinal and hepatic CYP3A activity, was not influenced by either the low (100 mg qd for 4 days) or high (600 mg qd for 4 days) RG 12525 dosing regimen despite the resulting total plasma concns. of inhibitor that were well above in vitro Ki values. The point ests. and 90% confidence intervals for the ratios of mean midazolam AUC for subjects administered 100 mg RG 12525 (110.6; 98.7-124.1) and 600 mg RG 12525 (98.4; 84.4-114.7) vs. midazolam alone were within 80% to 125%. To explain these results, factors that could limit the accuracy of in vitro models in predicting metabolic drug interactions, mainly the high degree of RG 12525 protein binding (> 99.9%), were considered. The lack of correlation between the in vitro inhibition of CYP3A4 by RG 12525 and the inconsequential effects of this compd. on midazolam pharmacokinetics accentuate the need to recognize factors other than plasma drug concns. and potency of in vitro enzyme inhibition when extrapolating in vitro data to predict in vivo drug-drug interactions.

IT **120128-20-3**, RG 12525
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(correlation between in vitro inhibition of CYP3A-mediated metab. by PPAR-.gamma. agonist and effect on clin. pharmacokinetics of midazolam)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:208 CAPLUS
DOCUMENT NUMBER: 134:209644
TITLE: The Process Development of RG 12525 (2-{[4-(Tetrazol-5-ylmethylphenyl)-methoxy]phenoxymethyl}quinoline)
AUTHOR(S): Bridge, Andrew W.; Jones, Ronald H.; Kabir, Humayun; Kee, Alex A.; Lythgoe, David J.; Nakach, Mustafa; Pemberton, Clive; Wrightman, John A.
CORPORATE SOURCE: Process Development Aventis Pharma Ltd., Dagenham Essex, RM10 7XS, UK

Searched by Barb O'Bryen, STIC 308-4291

SOURCE: Organic Process Research & Development (2001), 5(1), 9-15
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This contribution describes process improvements to provide a practical and cost-effective synthesis for the manuf. of RG 12525 which resulted in a 3-fold increase in overall yield. Improved solvent systems for chlorination and azidation reactions are described. Adjustments to the tetrazole-forming step eliminated azide sublimation and minimized this risk on scale-up. A robust solvent system was found to control the polymorphic form during crystn., which had hitherto been difficult due to the near-equivalence of m.ps. (154 and 157 .degree.C) of the two known forms.

IT **120128-20-3P**, RG 12525
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process improvement for prepn. of)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:772613 CAPLUS
DOCUMENT NUMBER: 133:335164
TITLE: Tri-aryl acid derivatives as PPAR receptor ligands
INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.; Labaudiniere, Richard F.; Zhang, Litao; Caulfield, Thomas J.; Minnich, Anne; Bobko, Mark; Morris, Robert; Groneberg, Robert D.; Mcgarry, Daniel G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064876	A1	20001102	WO 2000-US11490	20000428

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

applicant

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1177176 A1 20020206 EP 2000-930210 20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
BR 2000010126 A 20020226 BR 2000-10126 20000428
NO 2001005226 A 20011205 NO 2001-5226 20011025
PRIORITY APPLN. INFO.: US 1999-131454P P 19990428
WO 2000-US11490 W 20000428
OTHER SOURCE(S): MARPAT 133:335164
GI



I



II

AB This invention is directed to triaryl acid derivs. I and their salts, N-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkemyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, NHCONH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonylaminocarbonyl, sulfonylamino, carbamoyl, tetrazolyl, etc.; R1, R3, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-5; p = 0-4; q = 0-6; with numerous provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid underwent a sequence of: (1) Me esterification, (2) benzylic monobromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alk. hydrolysis with NaOH in aq. EtOH, to give title compd. II.

IT **303221-48-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of tri-aryl acid derivs. as PPAR receptor ligands)

RN 303221-48-9 CAPLUS

CN Benzoic acid, 2-[[3-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT 120128-20-3P 123225-57-0P 123225-58-1P
123225-59-2P 123225-60-5P 123225-64-9P
123225-66-1P 123225-67-2P 123225-69-4P
123225-71-8P 123225-73-0P 123225-75-2P
123225-76-3P 123225-78-5P 123225-80-9P
123225-81-0P 123225-82-1P 123225-94-5P
123225-95-6P 123225-96-7P 123225-97-8P
123225-98-9P 123225-99-0P 123226-00-6P
123226-01-7P 123226-03-9P 123226-04-0P
123226-05-1P 123226-07-3P 123226-08-4P
123226-09-5P 123226-11-9P 123226-13-1P
123226-14-2P 123226-15-3P 123226-16-4P
123226-17-5P 123226-18-6P 123226-19-7P
123226-20-0P 123226-21-1P 123226-22-2P
123226-23-3P 123226-24-4P 123226-25-5P
123226-26-6P 123226-27-7P 123247-23-4P
123247-24-5P 123247-25-6P 123247-27-8P
123247-28-9P 123692-25-1P 123692-28-4P
123692-29-5P 123692-36-4P 123692-37-5P
123692-38-6P 123692-39-7P 123692-40-0P
123715-60-6P 123791-11-7P 123791-12-8P
123791-15-1P 123791-16-2P 123791-17-3P
123791-18-4P 124993-46-0P 128760-03-2P
128760-51-0P 128760-53-2P 128760-54-3P
128760-55-4P 128760-56-5P 128760-57-6P
128760-59-8P 128760-60-1P 128760-61-2P
128760-62-3P 128760-69-0P 128760-73-6P
128760-74-7P 128760-75-8P 133628-51-0P
133628-56-5P 134138-98-0P 223771-70-8P
223771-76-4P 223771-79-7P 223771-81-1P
223772-08-5P 223772-12-1P 223772-14-3P
223772-15-4P 223772-18-7P 223772-26-7P
223772-42-7P 223772-43-8P 223772-45-0P
223772-46-1P 223772-47-2P 303216-72-0P
303216-78-6P 303216-82-2P 303216-84-4P
303216-91-3P 303216-94-6P 303216-98-0P
303217-06-3P 303217-08-5P 303217-10-9P
303217-12-1P 303217-15-4P 303217-18-7P
303217-21-2P 303217-27-8P 303217-33-6P
303217-46-1P 303217-48-3P 303217-73-4P
303217-76-7P 303217-81-4P 303217-83-6P
303217-85-8P 303217-87-0P 303217-89-2P
303217-91-6P 303217-93-8P 303217-95-0P
303217-97-2P 303217-99-4P 303218-01-1P
303218-03-3P 303218-05-5P 303218-07-7P
303218-09-9P 303218-11-3P 303218-13-5P
303218-17-9P 303218-19-1P 303218-21-5P
303218-23-7P 303218-25-9P 303218-27-1P
303218-29-3P 303218-31-7P 303218-33-9P
303218-35-1P 303218-37-3P 303218-39-5P
303218-41-9P 303218-43-1P 303218-45-3P
303218-47-5P 303218-49-7P 303218-51-1P

303218-53-3P 303218-55-5P 303218-57-7P
303218-59-9P 303218-63-5P 303218-65-7P
303218-67-9P 303218-69-1P 303218-71-5P
303218-73-7P 303218-75-9P 303218-77-1P
303218-79-3P 303218-81-7P 303218-83-9P
303218-85-1P 303218-87-3P 303218-89-5P
303218-91-9P 303218-93-1P 303218-95-3P
303218-97-5P 303218-99-7P 303219-01-4P
303219-03-6P 303219-05-8P 303219-07-0P
303219-11-6P 303219-13-8P 303219-15-0P
303219-17-2P 303219-19-4P 303219-21-8P
303219-23-0P 303219-25-2P 303219-27-4P
303219-29-6P 303219-31-0P 303219-33-2P
303219-35-4P 303219-37-6P 303219-39-8P
303219-41-2P 303219-43-4P 303219-45-6P
303219-47-8P 303219-49-0P 303219-51-4P
303219-53-6P 303219-55-8P 303219-57-0P
303219-59-2P 303219-65-0P 303219-67-2P
303219-69-4P 303219-71-8P 303219-73-0P
303219-75-2P 303219-77-4P 303219-78-5P
303219-80-9P 303219-82-1P 303219-84-3P
303219-86-5P 303219-88-7P 303219-90-1P
303219-92-3P 303219-94-5P 303219-96-7P
303219-98-9P 303220-00-0P 303220-02-2P
303220-04-4P 303220-06-6P 303220-08-8P
303220-10-2P 303220-12-4P 303220-14-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tri-aryl acid derivs. as PPAR receptor ligands)

RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-57-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-58-1 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-59-2 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-60-5 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-64-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-66-1 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-67-2 CAPLUS

CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-69-4 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-71-8 CAPLUS
CN Benzoic acid, 3-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-73-0 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-3-(1H-tetrazol-5-ylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-75-2 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-76-3 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-78-5 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-80-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-81-0 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-82-1 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-94-5 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-95-6 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-96-7 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-97-8 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl

]- (9CI) (CA INDEX NAME)



RN 123225-98-9 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl
]- (9CI) (CA INDEX NAME)



RN 123225-99-0 CAPLUS
CN Acetic acid, [4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI)
(CA INDEX NAME)



RN 123226-00-6 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methy
l]- (9CI) (CA INDEX NAME)



RN 123226-01-7 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI)
(CA INDEX NAME)



RN 123226-03-9 CAPLUS

CN Propanoic acid, 2-[2-[[4-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]ph
enoxy]- (9CI) (CA INDEX NAME)



RN 123226-04-0 CAPLUS
CN Acetic acid, [2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI)
(CA INDEX NAME)



RN 123226-05-1 CAPLUS
CN Acetic acid, [3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI)
(CA INDEX NAME)



RN 123226-07-3 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl
]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-08-4 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-09-5 CAPLUS
CN Pentanedioic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-11-9 CAPLUS
CN Pentanoic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-13-1 CAPLUS
CN Pentanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-14-2 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[4-(2-quinolinylmethoxy)phenoxy]methyl
]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-15-3 CAPLUS
CN Propanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-16-4 CAPLUS
CN Pentanedioic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-17-5 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-18-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-19-7 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen

oxy]- (9CI) (CA INDEX NAME)



RN 123226-20-0 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]- (9CI) (CA INDEX NAME)



RN 123226-21-1 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]- (9CI) (CA INDEX NAME)



RN 123226-22-2 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen
oxy]- (9CI) (CA INDEX NAME)



RN 123226-23-3 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-24-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-25-5 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-26-6 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 123226-27-7 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-23-4 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-24-5 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 123247-25-6 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-27-8 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123247-28-9 CAPLUS
CN Acetic acid, [6-acetyl-2-propyl-3-[[3-(2-quinolinylmethoxy)phenyl]methoxy] phenoxy]- (9CI) (CA INDEX NAME)



RN 123692-25-1 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 CAPLUS
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-11-7 CAPLUS
CN Quinoline, 2-[[4-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-12-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 123791-15-1 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-16-2 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 123791-17-3 CAPLUS
CN Quinoline, 2-[[3-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-18-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 124993-46-0 CAPLUS
CN Quinoline, 2-[2-[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 128760-03-2 CAPLUS
CN Propanoic acid, 2-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-51-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-53-2 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-54-3 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-55-4 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 128760-56-5 CAPLUS
CN Acetamide, 2-[4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-57-6 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 128760-59-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-60-1 CAPLUS
CN Propanoic acid, 2-[2-propyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-61-2 CAPLUS
CN Acetic acid, [4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-62-3 CAPLUS
CN Acetic acid, [4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-69-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-73-6 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-74-7 CAPLUS
CN Quinoline, 8-fluoro-2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-75-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 133628-51-0 CAPLUS
CN 2H-1-Benzopyran-2-propanoic acid, 3,4-dihydro-2-methyl-4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 133628-56-5 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 6-chloro-4-oxo-5-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 134138-98-0 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 223771-70-8 CAPLUS
CN Acetic acid, [2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223771-76-4 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-79-7 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-81-1 CAPLUS
CN Acetic acid, [2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-08-5 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-12-1 CAPLUS
CN Benzeneacetic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-14-3 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-15-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 223772-18-7 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-26-7 CAPLUS
CN Acetic acid, [2-methyl-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-42-7 CAPLUS
CN Propanoic acid, 2-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-43-8 CAPLUS
CN Benzeneacetic acid, 2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-45-0 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-47-2 CAPLUS
CN Quinoline, 2-[[3-[[2-(chloromethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-72-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-78-6 CAPLUS
CN Quinoline, 2-[[[1-methyl-3-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-82-2 CAPLUS
CN Quinoline, 2-[[[1-methyl-3-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-84-4 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-91-3 CAPLUS
CN Quinoline, 2-[[[1-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303216-94-6 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303216-98-0 CAPLUS
CN Quinoline, 2-[[[1-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-1H-indol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-06-3 CAPLUS
CN 3-Furancarboxylic acid, 2-methyl-5-[4-(2-quinolinylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303217-08-5 CAPLUS
CN 3-Furancarboxylic acid, 2-methyl-5-[4-(2-quinolinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 303217-10-9 CAPLUS
CN Quinoline, 2-[[[5,6,7,8-tetrahydro-7-[[3-(1H-tetrazol-5-yl)phenyl]methyl]-2-naphthalenyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-12-1 CAPLUS
CN 1H-Indole-3-carboxylic acid, 1-methyl-5-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303217-15-4 CAPLUS
CN Benzamide, 3-[[1,2,3,4-tetrahydro-7-(2-quinolinylmethoxy)-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-18-7 CAPLUS
CN Benzoic acid, 3-[[1,2,3,4-tetrahydro-7-(2-quinolinylmethoxy)-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-21-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-7-(2-quinolinylmethoxy)-2-[[3-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303217-27-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 303217-33-6 CAPLUS
CN Propanoic acid, 2-[2-[[4-[2-(7-chloro-2-quinolinyl)ethenyl]phenoxy]methyl] phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-46-1 CAPLUS
CN Quinoline, 2-[(1E)-2-[4-[(1E)-2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 303217-48-3 CAPLUS
CN Quinoline, 2-[(1E)-2-[4-[(1Z)-2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 303217-73-4 CAPLUS
CN Pentanedioic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-, 5-methyl ester (9CI) (CA INDEX NAME)



RN 303217-76-7 CAPLUS
CN Acetic acid, [3-[2-oxo-2-[3-(2-quinolinylmethoxy)phenyl]-1-(2-quinolinylmethyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-81-4 CAPLUS
CN Benzenepropanoic acid, 2-[[3-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-.alpha.-propyl- (9CI) (CA INDEX NAME)



RN 303217-83-6 CAPLUS
CN Pentanoic acid, 2-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-85-8 CAPLUS
CN Pentanoic acid, 2-[2-[2-[4-[[(7-chloro-2-quinolinyl)oxy]methyl]phenyl]ethenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303217-87-0 CAPLUS
CN Benzeneacetic acid, 3-[[4-(2-phenylethenyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303217-89-2 CAPLUS
CN Quinoline, 2-[[4-[2-[2-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-91-6 CAPLUS
CN Benzoic acid, 2-methoxy-6-methyl-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303217-93-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 303217-95-0 CAPLUS
CN 2-Benzofurancarboxylic acid, 7-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-97-2 CAPLUS
CN Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303217-99-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-01-1 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-methyl-5-(2-quinolinylmethoxy)phenoxy]methyl] phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-03-3 CAPLUS
CN Acetic acid, [2-[[2-bromo-5-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-05-5 CAPLUS
CN Acetic acid, [2-[[4-bromo-3-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-07-7 CAPLUS
CN 1H-Indole-1-acetic acid, 3-[[3-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 303218-09-9 CAPLUS
CN Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-11-3 CAPLUS
CN Benzoic acid, 3-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-13-5 CAPLUS
CN Benzoic acid, 2-methoxy-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-17-9 CAPLUS
CN Benzoic acid, 2-[[3-[2-(5-ethyl-2-pyridinyl)ethoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-19-1 CAPLUS
CN Benzoic acid, 2-[[3-[(4-ethylphenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-21-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-23-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-phenoxyphenyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-25-9 CAPLUS
CN Benzoic acid, 2-methyl-4-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 303218-27-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-29-3 CAPLUS
CN Benzoic acid, 5-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-31-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-methylphenyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-33-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-35-1 CAPLUS
CN Benzoic acid, 2-[[3-[(3-bromophenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-37-3 CAPLUS
CN Benzoic acid, 2-[[3-[[4-(1,1-dimethylethyl)phenyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-39-5 CAPLUS
CN Benzoic acid, 2-[[3-[[4-(1,1-dimethylethyl)cyclohexyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-41-9 CAPLUS

CN Benzeneacetic acid, 2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-43-1 CAPLUS
CN Acetic acid, [2-[[2-acetyl-5-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-45-3 CAPLUS
CN Benzoic acid, 4-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303218-47-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-49-7 CAPLUS
CN Benzoic acid, 2-[[3-[(5-ethyl-2-pyridinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-51-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[4-(1-methylethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-53-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinoxalinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-55-5 CAPLUS
CN Benzoic acid, 2-[[3-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-57-7 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinoxalinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-59-9 CAPLUS
CN Acetic acid, [2-[[3-[(6-methoxy-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-63-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-65-7 CAPLUS
CN Acetic acid, [4-chloro-2-methyl-6-[[3-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-67-9 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(carboxymethoxy)-3-methylphenyl]methoxy]phenyl]methoxy]-6-methyl-4-(phenylmethoxy)-, 1-ethyl ester (9CI) (CA INDEX NAME)



RN 303218-69-1 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[2-(2-quinolinyl)ethyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-71-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-73-7 CAPLUS
CN Acetic acid, [2-[[3-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-75-9 CAPLUS
CN Acetic acid, [2-[[3-(2-benzothiazolylmethoxy)phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-77-1 CAPLUS
CN Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 303218-79-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-pyridinyloxy)ethoxy]phenyl]methoxy]-
(9CI) (CA INDEX NAME)



RN 303218-81-7 CAPLUS
CN Acetic acid, [4-chloro-2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]methoxy
]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-83-9 CAPLUS
CN Acetic acid, [4-chloro-2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]
phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-85-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-thiazolyl)methoxy]phenoxy]methyl
]- (9CI) (CA INDEX NAME)



RN 303218-87-3 CAPLUS
CN Benzoic acid, 2-[[3-[(2,5-dimethylphenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303218-89-5 CAPLUS
CN Acetic acid, [2-[[3-[(4-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-91-9 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(carboxymethoxy)-3-methylphenyl]methoxy]phenyl]methoxy]-6-methyl-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 303218-93-1 CAPLUS
CN Acetic acid, [4-chloro-2-methoxy-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-95-3 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[2-(2-pyridinyloxy)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303218-97-5 CAPLUS
CN Acetic acid, [2-[[3-[(7-chloro-3-isoquinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303218-99-7 CAPLUS
CN Acetic acid, [2-[[3-[(6,7-dichloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-01-4 CAPLUS
CN Acetic acid, [2-[[3-[(6,7-difluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-03-6 CAPLUS
CN Acetic acid, [2-[[3-[(6,8-difluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-05-8 CAPLUS
CN Acetic acid, [2-(1,1-dimethylethyl)-6-[[3-(2-quinolinylmethoxy)phenoxy]met

hyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-07-0 CAPLUS
CN Acetic acid, [2-[[3-[(1-oxido-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-11-6 CAPLUS
CN Benzoic acid, 4-methoxy-2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303219-13-8 CAPLUS
CN Acetic acid, [2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-15-0 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[(2-quinolinylmethoxy)methyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-17-2 CAPLUS
CN Acetic acid, [2-[[3-[[(6-methoxy-2-quinolinyl)methoxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-19-4 CAPLUS
CN Acetic acid, [2-[[3-[[(4-chloro-2-quinolinyl)methoxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-21-8 CAPLUS
CN Propanoic acid, 2-[2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-23-0 CAPLUS
CN Acetic acid, [2-[[3-[(1,4-dihydro-1-methyl-4-oxo-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-25-2 CAPLUS
CN Acetic acid, [2,4-dichloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-27-4 CAPLUS
CN Benzoic acid, 2-[[3-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-29-6 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-31-0 CAPLUS
CN Benzoic acid, 2-[[3-[(6-methoxy-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-33-2 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-naphthalenylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-35-4 CAPLUS

CN Acetic acid, [2-[[3-[[4-(1,1-dimethylethyl)phenyl]methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-37-6 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-phenoxyethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-39-8 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(3-phenylpropoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-41-2 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[(3-phenoxyphenyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-43-4 CAPLUS
CN Acetic acid, [2-[[3-[(3-methoxyphenyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-45-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303219-47-8 CAPLUS
CN Acetic acid, [2-[[3-[(3,4-dichlorophenyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-49-0 CAPLUS
CN Benzoic acid, 2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-51-4 CAPLUS
CN Acetic acid, [2,4-dichloro-6-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-53-6 CAPLUS
CN Benzoic acid, 2-[[3-[(2,4-dichlorophenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-55-8 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-57-0 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-59-2 CAPLUS
CN Benzoic acid, 2-[[3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-65-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-pyridinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-67-2 CAPLUS
CN Acetic acid, [4-chloro-2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methy

l]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303219-69-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(phenylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-71-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-pyridinylmethoxy)methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-73-0 CAPLUS
CN Quinoline, 2-[[3-[[5-chloro-3-methyl-2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-75-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-quinolinylmethoxy)methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-77-4 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303219-78-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[2-(5-methyl-2-thienyl)-4-oxazolyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-80-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-82-1 CAPLUS
CN Benzoic acid, 2-[[3-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-84-3 CAPLUS

CN Benzoic acid, 2-[[3-[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-86-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2,4,5-trimethylphenyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-88-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-methyl-2-naphthalenyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-90-1 CAPLUS
CN Benzoic acid, 2-[[3-[(5-acetyl-2-methoxyphenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-92-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-quinolinyloxy)methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-94-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(6-phenyl-2-pyridinyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-96-7 CAPLUS
CN Benzoic acid, 2-[[3-[(6-chloro-2-pyridinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-98-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(1-naphthalenylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-00-0 CAPLUS

CN Benzoic acid, 2-[[3-([1,1'-biphenyl]-4-ylmethoxy)phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-02-2 CAPLUS
CN Benzoic acid, 2-[[3-[[2,4-bis(trifluoromethyl)phenyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-04-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[5-methyl-2,4-bis(1-methylethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-06-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(methyl-2-quinolinylamino)methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-08-8 CAPLUS
CN Benzoic acid, 2-[[3-[(2-benzoxazolylmethylamino)methyl]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-10-2 CAPLUS
CN Benzoic acid, 2-[[3-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-12-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-14-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



IT **303220-16-8P 303220-18-0P 303220-20-4P**
303220-22-6P 303220-24-8P 303220-26-0P
303220-28-2P 303220-30-6P 303220-32-8P
303220-34-0P 303220-36-2P 303220-45-3P
303220-49-7P 303220-74-8P 303220-76-0P
303220-78-2P 303220-80-6P 303220-82-8P
303220-84-0P 303220-86-2P 303220-88-4P
303220-90-8P 303220-94-2P 303220-96-4P
303220-98-6P 303221-00-3P 303221-02-5P
303221-04-7P 303221-06-9P 303221-08-1P
303221-10-5P 303221-12-7P 303221-14-9P
303221-16-1P 303221-18-3P 303221-20-7P
303221-22-9P 303221-24-1P 303221-26-3P
303221-28-5P 303221-30-9P 303221-32-1P
303221-34-3P 303221-36-5P 303221-38-7P

303221-40-1P 303221-42-3P 303221-44-5P
303221-46-7P 303221-50-3P 303221-52-5P
303221-54-7P 303221-56-9P 303221-58-1P
303221-60-5P 303221-62-7P 303221-64-9P
303221-66-1P 303221-68-3P 303221-70-7P
303221-72-9P 303221-74-1P 303221-76-3P
303221-79-6P 303221-82-1P 303221-85-4P
303221-87-6P 303221-89-8P 303221-91-2P
303221-93-4P 303221-97-8P 303221-99-0P
303222-03-9P 303222-05-1P 303222-07-3P
303222-09-5P 303222-10-8P 303222-12-0P
303222-14-2P 303222-16-4P 303222-18-6P
303222-20-0P 303222-22-2P 303222-24-4P
303222-28-8P 303222-30-2P 303222-32-4P
303222-34-6P 303222-36-8P 303222-38-0P
303222-40-4P 303222-42-6P 303222-44-8P
303222-46-0P 303222-48-2P 303222-50-6P
303222-52-8P 303222-54-0P 303222-56-2P
303222-58-4P 303222-60-8P 303222-62-0P
303222-64-2P 303222-66-4P 303222-68-6P
303222-70-0P 303222-72-2P 303222-74-4P
303222-77-7P 303222-79-9P 303222-81-3P
303222-85-7P 303222-88-0P 303222-90-4P
303222-92-6P 303222-94-8P 303222-96-0P
303222-98-2P 303223-00-9P 303223-02-1P
303223-04-3P 303223-06-5P 303223-08-7P
303223-10-1P 303223-12-3P 303223-14-5P
303223-16-7P 303223-18-9P 303223-20-3P
303223-22-5P 303223-24-7P 303223-27-0P
303223-31-6P 303223-33-8P 303223-35-0P
303223-37-2P 303223-39-4P 303223-46-3P
303223-48-5P 303223-50-9P 303223-52-1P
303223-68-9P 303223-73-6P 303223-87-2P
303225-36-7P 303225-38-9P 303229-19-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tri-aryl acid derivs. as PPAR receptor ligands)

RN 303220-16-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)



RN 303220-18-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[1-(2-quinolinylmethyl)-1H-imidazol-5-yl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-20-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 303220-22-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[1-(2-quinolinylmethyl)-1H-imidazol-4-yl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-24-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-phenyl-2-pyridinyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-26-0 CAPLUS
CN Benzoic acid, 2-[[3-[(5-chloro-2-pyridinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-28-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-naphthalenylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-30-6 CAPLUS
CN Benzoic acid, 2-[[3-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-32-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-methyl-2-quinoxalinyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-34-0 CAPLUS
CN Benzoic acid, 2-[[3-[(2-chlorophenyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303220-36-2 CAPLUS

CN Acetic acid, [2-methyl-6-[[3-[(2-phenyl-4-thiazolyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303220-45-3 CAPLUS
CN Benzeneacetic acid, .alpha.-methyl-2-[[3-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-49-7 CAPLUS
CN Benzoic acid, 2-methyl-4-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303220-74-8 CAPLUS
CN Acetic acid, [2-[2-[4-(2-quinolinylmethoxy)phenyl]-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303220-76-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-78-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-80-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-pyridinyloxy)ethoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-82-8 CAPLUS
CN Benzoic acid, 2-[[3-[(2-benzoxazolylmethylamino)methyl]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-84-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(methyl-2-quinolinylamino)methyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-86-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-quinolinyloxy)methyl]phenoxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303220-88-4 CAPLUS
CN Benzoic acid, 2-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-90-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[4-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-94-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-pyridinylmethoxy)methyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-96-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-quinolinylmethoxy)methyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303220-98-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-00-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-thiazolyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-02-5 CAPLUS
CN Benzoic acid, 2-[[3-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-04-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-06-9 CAPLUS
CN Benzoic acid, 2-[[3-[(2,5-dimethylphenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-08-1 CAPLUS
CN Benzoic acid, 2-[[3-[(2,4-dichlorophenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-10-5 CAPLUS
CN Benzoic acid, 2-[[3-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-12-7 CAPLUS
CN Benzoic acid, 2-[[3-[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-14-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2,4,6-trimethylphenyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-16-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-methyl-2-naphthalenyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-18-3 CAPLUS
CN Benzoic acid, 2-[[3-[(5-acetyl-2-methoxyphenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-20-7 CAPLUS
CN Benzoic acid, 2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-22-9 CAPLUS
CN Benzoic acid, 2-[[3-[[4-(1,1-dimethylethyl)phenyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-24-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[4-(1-methylethyl)phenyl]methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-26-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-phenoxyphenyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-28-5 CAPLUS
CN Benzoic acid, 2-[[3-[[4-(1,1-dimethylethyl)cyclohexyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-30-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinoxalinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-32-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-methylphenyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-34-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[2-(5-methyl-2-thienyl)-4-oxazolyl]methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-36-5 CAPLUS
CN Benzoic acid, 2-[[3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-38-7 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-40-1 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-42-3 CAPLUS
CN Benzoic acid, 2-[[3-[(6-chloro-2-pyridinyl)methoxy]phenoxy]methyl]-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-44-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-46-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(phenylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-50-3 CAPLUS
CN Benzoic acid, 2-[[3-[(6-methoxy-2-quinolinyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-52-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[5-methyl-2,4-bis(1-methylethyl)phenyl]methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-54-7 CAPLUS
CN Benzoic acid, 2-[[3-[[2,4-bis(trifluoromethyl)phenyl]methoxy]phenoxy]methyl]-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-56-9 CAPLUS
CN Benzoic acid, 2-[[3-([1,1'-biphenyl]-4-ylmethoxy)phenoxy]methyl]-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-58-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(1-naphthalenylmethoxy)phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-60-5 CAPLUS
CN Benzoic acid, 2-[[3-[(5-ethyl-2-pyridinyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-62-7 CAPLUS
CN Benzoic acid, 2-[[3-[(4-ethylphenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-64-9 CAPLUS
CN Benzoic acid, 2-[[3-[(3-bromophenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-66-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-68-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-phenyl-2-pyridinyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-70-7 CAPLUS
CN Benzoic acid, 2-[[3-[(2-chlorophenyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-72-9 CAPLUS
CN Benzoic acid, 2-[[3-[(4-chlorophenyl)methoxy]phenoxy]methyl]-6-methyl-,

methyl ester (9CI) (CA INDEX NAME)



RN 303221-74-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(3-methyl-2-quinoxalinyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-76-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-naphthalenylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-79-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303221-82-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 303221-85-4 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303221-87-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-89-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-quinolinyl)ethoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-91-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(6-phenyl-2-pyridinyl)methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-93-4 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303221-97-8 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303221-99-0 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[2-(2-pyridinyloxy)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-03-9 CAPLUS
CN Acetonitrile, [2-[[3-[[(4-chloro-2-quinolinyl)methoxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-05-1 CAPLUS
CN Acetonitrile, [2-[[3-[[(6-methoxy-2-quinolinyl)methoxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-07-3 CAPLUS
CN Propanoic acid, 3-[2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303222-09-5 CAPLUS
CN Acetonitrile, [2,4-dichloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-10-8 CAPLUS
CN Acetonitrile, [4-chloro-2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-12-0 CAPLUS
CN Acetonitrile, [2-(1,1-dimethylethyl)-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-14-2 CAPLUS
CN Acetonitrile, [4-chloro-2-methoxy-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-16-4 CAPLUS
CN Benzonitrile, 2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303222-18-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303222-20-0 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303222-22-2 CAPLUS
CN 2-Benzofurancarboxylic acid, 7-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303222-24-4 CAPLUS
CN Acetonitrile, [4-chloro-2-methyl-6-[[3-[2-(2-pyridinyl)ethoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-28-8 CAPLUS
CN Benzeneacetonitrile, 2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303222-30-2 CAPLUS
CN Acetonitrile, [2-[[3-[(7-chloro-3-isoquinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-32-4 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(2-naphthalenylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-34-6 CAPLUS
CN Acetonitrile, [2-[[3-[[4-(1,1-dimethylethyl)phenyl]methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-36-8 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(2-phenoxyethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-38-0 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(3-phenylpropoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-40-4 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[(3-phenoxyphenyl)methoxy]phenoxy]methyl]phe

noxy]- (9CI) (CA INDEX NAME)



RN 303222-42-6 CAPLUS
CN Acetonitrile, [2-[[3-[(3-methoxyphenyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-44-8 CAPLUS
CN Acetonitrile, [2-[[3-[(3,4-dichlorophenyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-46-0 CAPLUS
CN Acetonitrile, [2-[[3-[(6,7-difluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-48-2 CAPLUS
CN Acetonitrile, [2-[[3-[(6,8-difluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-50-6 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[(1-oxido-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-52-8 CAPLUS
CN Acetonitrile, [2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-54-0 CAPLUS
CN Acetonitrile, [2-[[3-[(1,4-dihydro-1-methyl-4-oxo-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-56-2 CAPLUS
CN Acetonitrile, [2-[[3-[(4-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-58-4 CAPLUS
CN Acetonitrile, [2-[[3-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-60-8 CAPLUS
CN Acetonitrile, [2-[[3-[(6-methoxy-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-62-0 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(4-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-64-2 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(2-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-66-4 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(3-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-68-6 CAPLUS
CN Acetonitrile, [2-[[3-[(6,7-dichloro-2-quinolinyl)methoxy]phenoxy]methyl]-6-

methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-70-0 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[(2-phenyl-4-thiazolyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-72-2 CAPLUS
CN Acetonitrile, [4-chloro-2-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-74-4 CAPLUS
CN Acetonitrile, [2,4-dichloro-6-[[3-[(6-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-77-7 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(4-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-79-9 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-81-3 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(3-pyridinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-85-7 CAPLUS
CN Acetic acid, [2-[[3-[[(2,3-dihydro-1,3,3-trimethyl-2-oxo-1H-indol-6-yl)oxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303222-88-0 CAPLUS
CN Benzaldehyde, 2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 303222-90-4 CAPLUS

CN Acetonitrile, [4-chloro-2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]methoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303222-92-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]methoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303222-94-8 CAPLUS
CN Acetic acid, [2-[[4-bromo-3-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303222-96-0 CAPLUS
CN Acetic acid, [2-[[2-bromo-3-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303222-98-2 CAPLUS
CN Benzaldehyde, 2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303223-00-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 303223-02-1 CAPLUS
CN Acetic acid, [2-[[2-acetyl-5-(2-quinolinylmethoxy)phenoxy]methyl]-6-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-04-3 CAPLUS
CN Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303223-06-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303223-08-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303223-10-1 CAPLUS
CN Benzoic acid, 2-methyl-4-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-12-3 CAPLUS
CN Benzoic acid, 4-methoxy-2-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-14-5 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(cyanomethoxy)-3-methylphenyl]methoxy]phenyl]methoxy]-6-methyl-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-16-7 CAPLUS
CN Acetonitrile, [2-[[3-[[(2,3-dihydro-1,3,3-trimethyl-2-oxo-1H-indol-6-yl)oxy]methyl]phenoxy]methyl]-6-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 303223-18-9 CAPLUS
CN Benzoic acid, 2-hydroxy-4-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-20-3 CAPLUS
CN Benzoic acid, 2-methoxy-4-methyl-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-22-5 CAPLUS
CN Benzoic acid, 4-methyl-2-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303223-24-7 CAPLUS
CN Benzoic acid, 4-methyl-2-(phenylmethoxy)-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 303223-27-0 CAPLUS
CN Phenol, 3-[2-(5-ethyl-2-pyridinyl)ethoxy]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 303223-31-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]thio]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303223-33-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]sulfinyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303223-35-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-(2-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303223-37-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[1-(2-quinolinylmethyl)-1H-imidazol-4-yl]methoxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303223-39-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[1-(2-quinolinylmethyl)-1H-imidazol-5-yl]methoxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 303223-46-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[3-[[2-(hydroxymethyl)-3-methylphenyl]methoxy]phenoxy]methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 303223-48-5 CAPLUS
CN Benzenemethanol, 2-[[3-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303223-50-9 CAPLUS
CN Benzaldehyde, 2-[[3-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303223-52-1 CAPLUS
CN Benzaldehyde, 2-[[3-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303223-68-9 CAPLUS
CN Quinoline, 7-chloro-2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303223-73-6 CAPLUS
CN Propanedioic acid, [2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 303223-87-2 CAPLUS
CN Quinoline, 2-[[3-[[[2-methoxy-5-(1H-tetrazol-5-yl)phenyl]methoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303225-36-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[1-(2-quinolinylmethyl)-1H-imidazol-4-yl]methoxy]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 303220-22-6
CMF C23 H21 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 303225-38-9 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-(2-quinoxalinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 303229-19-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(2-quinolinyl)ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



IT **303225-23-2 303225-24-3 303225-25-4**
303225-26-5 303225-27-6 303225-34-5
303225-35-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of tri-aryl acid derivs. as PPAR receptor ligands)
RN 303225-23-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-(2-pyridinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303225-24-3 CAPLUS
CN Benzoic acid, 3-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303225-25-4 CAPLUS
CN Benzoic acid, 4-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303225-26-5 CAPLUS
CN Benzoic acid, 5-methoxy-2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303225-27-6 CAPLUS
CN Benzoic acid, 2-methoxy-6-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 303225-34-5 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-methyl-5-(2-quinolinylmethoxy)phenoxy]methyl] phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303225-35-6 CAPLUS
CN Acetonitrile, [2-methyl-6-[[3-[(2-quinolinylmethoxy)methyl]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:282096 CAPLUS
DOCUMENT NUMBER: 130:320864
TITLE: PPAR-.gamma.-binding quinoline derivatives, their preparation, and their therapeutic use
INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920275	A1	19990429	WO 1998-US21947	19981016
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2306825	AA	19990429	CA 1998-2306825	19981016
AU 9896961	A1	19990510	AU 1998-96961	19981016
ZA 9809465	A	20000417	ZA 1998-9465	19981016
EP 1030665	A1	20000830	EP 1998-951075	19981016
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO			
BR 9814087	A	20001003	BR 1998-14087	19981016
JP 2001520193	T2	20011030	JP 2000-516672	19981016
US 6376512	B1	20020423	US 2000-490897	20000127
NO 2000001962	A	20000616	NO 2000-1962	20000414

PRIORITY APPLN. INFO.: US 1997-62318P P 19971017
US 1997-65902P P 19971117
WO 1998-US21947 W 19981016
OTHER SOURCE(S): MARPAT 130:320864
GI



I

AB A method for mediating the activity of PPAR-.gamma. receptor comprises contacting the PPAR-.gamma. receptor with I [A = O, S, (R1)C=C(R1), bond; B = O, S, SO, SO2, NR1, bond; D = O, S, NR1, (R1)C=C(R1), bond; E = bond; a = 0-2; b = 0, 1; c = 0-4; d = 0-5; e = 0-4; f = 0-5; n = 0-2; R = H; R' = H; R1 = H; R2 = (CH2)qX, or two vicinal R2 taken together with the carbon atoms through which the two vicinal R2 are linked form cycloalkylene, etc.; q = 0-3; X = H]. Prepn. of I is described. The compds. may be used to treat cardiovascular conditions, diabetes, hyperlipidemia, hypertension, eating disorders, etc.

IT **123225-57-0P 123225-58-1P 123225-59-2P**
123225-60-5P 123225-64-9P 123225-69-4P
123225-71-8P 123225-76-3P 123225-82-1P
123225-94-5P 123225-95-6P 123225-96-7P
123225-98-9P 123225-99-0P 123226-00-6P
123226-01-7P 123226-03-9P 123226-04-0P
123226-05-1P 123226-07-3P 123226-08-4P
123226-09-5P 123226-11-9P 123226-13-1P
123226-14-2P 123226-15-3P 123226-16-4P
123226-17-5P 123226-19-7P 123226-20-0P
123226-21-1P 123226-25-5P 123226-27-7P
123247-23-4P 123247-25-6P 123247-27-8P
123247-28-9P 123692-25-1P 123692-29-5P
123692-37-5P 123692-38-6P 123692-39-7P
123791-11-7P 123791-15-1P 124993-46-0P
128760-62-3P 128760-73-6P 223772-08-5P
223772-12-1P 223772-14-3P 223772-15-4P
223772-18-7P 223772-26-7P 223772-42-7P
223772-43-8P 223772-45-0P 223772-46-1P
223772-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR-.gamma.-binding quinoline deriv. prepn. and therapeutic use)

RN 123225-57-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-58-1 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-59-2 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-60-5 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-64-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-69-4 CAPLUS

CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methy
l]- (9CI) (CA INDEX NAME)



RN 123225-71-8 CAPLUS
CN Benzoic acid, 3-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl
]- (9CI) (CA INDEX NAME)



RN 123225-76-3 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-
yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-82-1 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl
]- (9CI) (CA INDEX NAME)



RN 123225-94-5 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-
yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-95-6 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-96-7 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-98-9 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-99-0 CAPLUS
CN Acetic acid, [4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-00-6 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123226-01-7 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-03-9 CAPLUS
CN Propanoic acid, 2-[2-[[4-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-04-0 CAPLUS
CN Acetic acid, [2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-05-1 CAPLUS
CN Acetic acid, [3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-07-3 CAPLUS

CN Benzoic acid, 2-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-08-4 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-09-5 CAPLUS
CN Pentanedioic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-11-9 CAPLUS
CN Pentanoic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-13-1 CAPLUS
CN Pentanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-14-2 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-15-3 CAPLUS
CN Propanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-16-4 CAPLUS
CN Pentanedioic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-17-5 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-19-7 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-20-0 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-21-1 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-25-5 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-27-7 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-23-4 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-25-6 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-27-8 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123247-28-9 CAPLUS
CN Acetic acid, [6-acetyl-2-propyl-3-[[3-(2-quinolinylmethoxy)phenyl]methoxy] phenoxy]- (9CI) (CA INDEX NAME)



RN 123692-25-1 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-11-7 CAPLUS
CN Quinoline, 2-[[4-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-15-1 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 124993-46-0 CAPLUS
CN Quinoline, 2-[2-[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 128760-62-3 CAPLUS
CN Acetic acid, [4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-73-6 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-08-5 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-12-1 CAPLUS
CN Benzeneacetic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-14-3 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-15-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 223772-18-7 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223772-26-7 CAPLUS
CN Acetic acid, [2-methyl-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-42-7 CAPLUS
CN Propanoic acid, 2-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223772-43-8 CAPLUS
CN Benzeneacetic acid, 2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]- (9CI)

(CA INDEX NAME)



RN 223772-45-0 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 CAPLUS
CN Benzenebutanoic acid, 3-fluoro-.gamma.-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-47-2 CAPLUS
CN Quinoline, 2-[[3-[[2-(chloromethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



IT **120128-20-3 123225-67-2 123225-73-0 123225-80-9 123225-81-0 123225-97-8 123226-18-6 123226-22-2 123226-23-3 123226-24-4 123226-26-6 128760-51-0 128760-53-2 128760-60-1 128760-69-0 223771-70-8 223771-76-4 223771-79-7 223771-81-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PPAR-.gamma.-binding quinoline deriv. prepn. and therapeutic use)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-67-2 CAPLUS

CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-73-0 CAPLUS

CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-3-(1H-tetrazol-5-ylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-80-9 CAPLUS

CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-81-0 CAPLUS

CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-97-8 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123226-18-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-22-2 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-23-3 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-24-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-26-6 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 128760-51-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-53-2 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen

oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-60-1 CAPLUS
CN Propanoic acid, 2-[2-propyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 128760-69-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223771-70-8 CAPLUS
CN Acetic acid, [2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 223771-76-4 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-79-7 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 223771-81-1 CAPLUS
CN Acetic acid, [2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **123225-66-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(PPAR-.gamma.-binding quinoline deriv. prepn. and therapeutic use)
RN 123225-66-1 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



IT **123225-75-2P 123247-24-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; PPAR-.gamma.-binding quinoline deriv. prepn. and therapeutic use)
RN 123225-75-2 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 123247-24-5 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **123225-78-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; PPAR-.gamma.-binding quinoline deriv. prepn. and therapeutic use)
RN 123225-78-5 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:249435 CAPLUS
DOCUMENT NUMBER: 131:78541
TITLE: Application of evaporative light scattering detection to the characterization of combinatorial and parallel synthesis libraries for pharmaceutical drug discovery
AUTHOR(S): Hsu, Bih H.; Orton, Edward; Tang, Sheng-Yuh; Carlton, Robert A.
CORPORATE SOURCE: Spectroscopy Section, Pharmaceutical Discovery Research, Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA, 19426, USA
SOURCE: Journal of Chromatography, B: Biomedical Sciences and Applications (1999), 725(1), 103-112
CODEN: JCBBEP; ISSN: 0378-4347
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The advent of combinatorial and parallel synthesis methodologies in drug discovery have necessitated the development of anal. techniques which

permit high throughput quant. anal. of mixts. of small org. mols. HPLC with evaporative light scattering detection has become the major tool for this task. In this article we briefly review the theory of evaporative light scattering detection and the design of com. instruments, as well as discuss the operational constraints imposed by the exigency of analyzing en masse the product libraries generated by these new drug discovery methods. The application of evaporative light scattering detection to library anal. is illustrated using examples from our library synthesis program. Complemented by UV absorbance detection for purity assessment and mass spectrometry for product identification, evaporative light scattering detection is the only technique affording sufficient accuracy and sensitivity for high throughput library anal.

IT **120128-20-3**, RG 12525
RL: ANT (Analyte); ANST (Analytical study)
(application of evaporative light scattering detection to the characterization of combinatorial and parallel synthesis libraries for drug discovery)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:142813 CAPLUS
DOCUMENT NUMBER: 126:225257
TITLE: A convergent synthesis of an LTD4 antagonist, RG12525
AUTHOR(S): Sledeski, Adam W.; O'brien, Michael K.; Truesdale, Larry K.
CORPORATE SOURCE: Process Chemistry, Rhone-Poulenc Rorer Central Research, PLT, Collegeville, PA, 19426, USA
SOURCE: Tetrahedron Letters (1997), 38(7), 1129-1132
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 126:225257
GI



I



III

AB An efficient, convergent synthesis of an LTD4 antagonist, RG12525 (I) has been achieved through the alkylation of 4-(2-quinolinylmethoxy)phenol (II) with either a triphenylmethyl protected tetrazole synthon III or with the tetrahydropyranyl deriv. Prepn. of the synthons as well as novel prepn. of II is described.

IT **120128-20-3P**, RG12525
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tetrazolylmethylphenoxy quinoline RG12525)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:111522 CAPLUS

DOCUMENT NUMBER: 126:199509

TITLE: Approaches to p-hydroxyphenoxymethylquinolines which avoid intermediate chloromethylquinolines for the synthesis of the LTD4 antagonist, RG 12525

AUTHOR(S): O'Brien, M. K.; Sledeski, A. W.; Truesdale, L. K.

CORPORATE SOURCE: Process Chem., Rhone-Poulenc Rorer Central Res., Collegeville, PA, 19426, USA

SOURCE: Tetrahedron Letters (1997), 38(4), 509-512
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

Searched by Barb O'Bryen, STIC 308-4291

OTHER SOURCE(S): CASREACT 126:199509

AB As part of an effort to develop an industrial synthesis of the LTD4 antagonist RG 12525, several approaches to the intermediate (2-quinolinylmethoxy)phenol (I) were investigated that avoided the generation of the lachrymatory sensitizer .alpha.-chloro-2-methylquinoline. Utilization of a cyclic sulfate in place of .alpha.,.alpha.'-dichloro-o-xylene showed promise as a selective dialkylating agent in the conversion of I to RG 12525.

IT **120128-20-3P**, RG 12525
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of [(hydroxyphenoxy)methyl]quinoline and RG 12525)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:214900 CAPLUS

DOCUMENT NUMBER: 124:241893

TITLE: Preparation and characterization of polymorphs for an LTD4 antagonist, RG 12525

AUTHOR(S): Carlton, Robert A.; Difeo, Thomas J.; Powner, Tory H.; Santos, Ivan; Thompson, Michael D.

CORPORATE SOURCE: Rhone-Poulenc Rorer, Collegeville, PA, 19426, USA

SOURCE: Journal of Pharmaceutical Sciences (1996), 85(5), 461-7
CODEN: JPMSAE; ISSN: 0022-3549

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This report describes the prepn. and characterization of two polymorphic forms of RG 12525, a leukotriene D4 (LTD4) antagonist. Polymorph I is prepd. by recrystn. from methanol or titrn. of the sodium salt of RG 12525 with citric acid. Polymorph II is prepd. by recrystn. from methanol or titrn. of the ammonium salt of RG 12525 with citric acid. The polymorphic system is enantiotropic, with pure form I melting at 154.degree.C, 3 degrees less than the melting temp. of form II. Form I is thermodynamically more stable than form II at room temp. These polymorphic forms are differentiated using microscopy, differential scanning calorimetry (DSC), IR spectroscopy (IR), and powder X-ray diffraction (XRD) anal. Soly. properties from 31 to 72.degree.C were detd. to be similar for both forms. The calcd. solubilities at 25.degree.C are 7.6 and 9.8 .mu.M for forms I and II, resp. The free energy change from form II to form I at 25.degree.C is -0.15 kcal/mol. Thermodn. properties of the system are summarized using a schematic free energy diagram.

IT **120128-20-3**, RG 12525
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prepn. and characterization of polymorphs of leukotriene D4 antagonist RG 12525)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:547222 CAPLUS
DOCUMENT NUMBER: 125:237599
TITLE: A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists
AUTHOR(S): Hariprasad, V.; Kulkarni, Vithal M.
CORPORATE SOURCE: Pharmaceutical Div., Dep. Chem. Technology, Univ. Bombay, Bombay, 400019, India
SOURCE: Journal of Computer-Aided Molecular Design (1996), 10(4), 284-292
CODEN: JCADEQ; ISSN: 0920-654X
PUBLISHER: ESCOM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Mol. modeling studies were carried out by a combined use of conformational anal. and 3D-QSAR methods to identify mol. features common to a series of hydroxyacetophenone (HAP) and non-hydroxyacetophenone (non-HAP) peptide leukotriene (pLT) receptor antagonists. In attempts to develop a ligand-binding model for the pLT receptor, the Apex-3D program was used to identify biophoric structural patterns that are common to 13 diverse sets of compds. showing different levels of biol. activity. A systematic conformational anal. was carried out to obtain sterically accessible conformations for these flexible compds. Apex-3D was then utilized to propose common biophoric regions based on the selection of one of several conformations (MOPAC-minimized AM1) from each compd.'s data set that best fits the biophoric pattern and the resulting superimposition with all the other data-set compds. Apex-3D identified three common biophoric features important for activity: one as the hydroxyl, acetyl, carbonyl and carboxyl groups, which mimic the acid-binding region of an agonist, the other as the hydrogen-bond donating site, and the third part is represented by a plane in which lipophilic arom. groups align. The structure-activity relationships were then assessed by using the 3D-QSAR model. A common biophore model is proposed from the Apex-3D anal. which may be useful in designing new pLT antagonists. Mol. vols. and electrostatic potential similarities were also calcd. to obtain the important structural requirements for the activity.

IT **120128-20-3**, RG-12525
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proposed common spatial pharmacophore and corresponding active conformations of peptide leukotriene receptor antagonists detd. by QSAR)

RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:904661 CAPLUS
DOCUMENT NUMBER: 124:546
TITLE: Subchronic toxicity studies with the leukotriene D4 antagonist RG 12525
AUTHOR(S): Bonnefoi, Marc S.; Kelley, Michael F.; Wells, Roger E.; Sanders, James E.; Jayyosi, Zaid; Beys, Eric; Kornbrust, Douglas J.; Langloss, John M.
CORPORATE SOURCE: Drug Safety Div., Rhone-Poulenc Rorer Cent. Res., Collegeville, PA, 19426-0107, USA
SOURCE: Fundamental and Applied Toxicology (1995), 28(1), 129-38
CODEN: FAATDF; ISSN: 0272-0590
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Preclin. safety studies with the leukotriene D4 antagonist RG 12525 were conducted by the oral route in mice, rats, and monkeys. Oral administration of RG 12525 was repeated daily in studies up to 6 mo in duration. RG 12525 was shown to have limited high-dose toxicity after repeated oral administration. The effects of RG 12525 were strongly dependent upon the species considered. High doses of RG 12525 caused significant increases in liver wt. in mice, rats, and monkeys that were assocd. with diffuse hepatocellular hypertrophy in mice and rats but not in monkeys. No related clin. chem. changes were obsd. in any of the species and hepatic activities of peroxisomal enzymes or cytochrome P 450 were increased only slightly. Proliferation of brown adipose tissue (BAT) was obsd. in rats and mice but not in monkeys. The BAT reaction was more pronounced in the interscapular area but it was also obsd. in other s.c. locations as well as in mediastinal and bone marrow fat. In all locations, the RG 12525-induced BAT had some morphol. similarities with cold-adapted BAT. Repeated administration of RG 12525 at high doses to female rats resulted in a lack of progression to the luteal phase of the estrous cycle that was reversible after discontinuation of treatment. Finally, RG 12525 was nephrotoxic in mice with males being more sensitive than females.

IT **120128-20-3**, RG 12525
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(subchronic toxicity studies with leukotriene D4 antagonist RG 12525)
RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:414418 CAPLUS
DOCUMENT NUMBER: 117:14418
TITLE: Antiallergic compositions containing platelet-activating factor antagonists and leukotriene D4 antagonists
INVENTOR(S): O'Donnell, Margaret; Welton, Ann
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., A.-G., Switz.
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 469477	A1	19920205	EP 1991-112577	19910726
EP 469477	B1	19950920		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
AT 128030	E	19951015	AT 1991-112577	19910726
CA 2048236	AA	19920203	CA 1991-2048236	19910731
ZA 9106036	A	19920527	ZA 1991-6036	19910731
AU 9181535	A1	19920213	AU 1991-81535	19910801
AU 651358	B2	19940721		
JP 04244028	A2	19920901	JP 1991-216009	19910801
US 5227378	A	19930713	US 1992-848564	19920309

PRIORITY APPLN. INFO.: US 1990-561743 19900802

AB A synergistic combination of platelet activating factor (PAF) antagonists with leukotriene D4 (LTD4) antagonists provides protection against allergic reactions, such as antigen-induced death. Guinea pigs were sensitized with an i.p. injection of ovalbumin in a saline soln. and administered with a combination of 5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]phenanthridin-6(5H)-one (I) (PAF antagonist) and (E)-4-[3-[2-(4-cyclobutyl-2-thiazolyl)ethenyl]phenylamino]-2,2-diethyl-4-oxobutanoic acid (II) (LTD4 antagonist) at 1 mg/kg each before challenge with antigen; a survival rate from anaphylactic death at 120 min was 100 %, compared to 0 % for groups administered with I or II alone. Formulations contg. I and II combinations are given.

IT **120128-20-3D**, mixts. with platelet-activating factor antagonists
RL: BIOL (Biological study)
(antiallergic compns. contg.)
RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:247098 CAPLUS
DOCUMENT NUMBER: 114:247098
TITLE: Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 4. Addition of chromone moiety enhances leukotriene D4 receptor binding affinity
AUTHOR(S): Huang, Fu Chih; Galemmo, Robert A., Jr.; Poli, Gregory B.; Learn, Keith S.; Morrissette, Mathew M.; Johnson, William H., Jr.; Dankulich, William P.; Campbell, Henry F.; Carnathan, Gilbert W.; Van Inwegen, Richard G.
CORPORATE SOURCE: Rhone-Poulenc Rorer Cent. Res., King of Prussia, PA, 19406, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(5), 1704-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:247098
GI



I

AB The combination of the benzopyran-4-one ring, a moiety found in the prototype leukotriene antagonist, FPL 55,712, with the (2-quinolinylmethoxy)phenyl group led to a significant increase in leukotriene receptor binding affinity. This modification resulted in a 10,000-fold improvement in binding affinity compared to FPL 55,712. Chromanone I (RG 12553), with Ki value of 0.1 nM, has higher affinity than the natural agonist LTD4 and is one of the most potent LTD4 antagonists reported. The structure-activity relationships of this series of potent leukotriene antagonists are discussed.

IT **133628-51-0P 133628-56-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and radioligand binding assay of, on guinea pig lung membranes)
RN 133628-51-0 CAPLUS
CN 2H-1-Benzopyran-2-propanoic acid, 3,4-dihydro-2-methyl-4-oxo-7-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 133628-56-5 CAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 6-chloro-4-oxo-5-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



IT **120128-20-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(radioligand binding assay of, on guinea pig lung membranes)
RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:138891 CAPLUS
DOCUMENT NUMBER: 112:138891
TITLE: Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity
AUTHOR(S): Huang, Fu Chih; Galemmo, Robert A., Jr.; Johnson, William H., Jr.; Poli, Gregory B.; Morrissette, Matthew M.; Mencel, James J.; Warus, James D.; Campbell, Henry F.; Nuss, George W.; et al.
CORPORATE SOURCE: Rorer Cent. Res., Horsham, PA, 19044, USA
SOURCE: Journal of Medicinal Chemistry (1990), 33(4), 1194-200

Searched by Barb O'Bryen, STIC 308-4291

CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:138891
GI



I

AB Orally active, highly potent, specific antagonists, e.g., I X = 3-, 4-OCH2, 3-, 4-CH2O, 3-CH:CH,3-CH2CH2, X1 = 3-yl, 4-yl, 2-, 3-, 4-CH2, 2-, 3-, 4-OCH2) of the peptidoleukotrienes contg. a (2-quinolinylmethoxy)phenyl moiety were prepd. The compds. contain an addnl. Ph ring, which has significantly improved the receptor affinity. The effect of changes in the linkage between the two Ph rings as well as the orientation of the acidic functional group on biol. activity are discussed. Many I have high affinity to the sulfidopeptide leukotriene D4 receptors with Ki values ranging between 2 and 20 nM and are orally active. I (X = 4-OCH2, X1 = 2-CH2) represents the best combination of in vitro and in vivo biol. activity in this series and has been selected for further evaluation in clin. studies of asthma.

IT **123225-66-1 123225-67-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(leukotriene antagonist activity of)

RN 123225-66-1 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-67-2 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



IT **120128-20-3P 123225-57-0P 123225-58-1P**
123225-60-5P 123225-64-9P 123225-69-4P
123225-73-0P 123225-76-3P 123225-80-9P
123225-81-0P 123225-82-1P 123225-95-6P
123225-96-7P 123225-97-8P 123225-98-9P
123226-00-6P 123226-27-7P 123247-23-4P

123247-25-6P 123692-28-4P 124993-46-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and leukotriene antagonist activity of)

RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-57-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-58-1 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-60-5 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-64-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-69-4 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-73-0 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-3-(1H-tetrazol-5-ylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-76-3 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-80-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-81-0 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-82-1 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-95-6 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-96-7 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-97-8 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-98-9 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123226-00-6 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methy l]- (9CI) (CA INDEX NAME)



RN 123226-27-7 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-23-4 CAPLUS

CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-25-6 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 124993-46-0 CAPLUS
CN Quinoline, 2-[2-[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:497461 CAPLUS
DOCUMENT NUMBER: 113:97461
TITLE: Preparation of quinoline derivatives useful as lipoxygenase inhibitors and/or leukotriene antagonists
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: PCT Int. Appl., 54 pp.

Searched by Barb O'Bryen, STIC 308-4291

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8912629	A1	19891228	WO 1989-US2692	19890620
W: JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4918081	A	19900417	US 1988-210468	19880620

PRIORITY APPLN. INFO.: US 1988-210468 19880620
OTHER SOURCE(S): CASREACT 113:97461; MARPAT 113:97461
GI



I



II

AB Title compds. I [R2 = H, alkyl, OH, alkoxy, CO2H, carbalkoxy, halo, NO2, haloalkyl, cyano, acyl; R1 = H, alkyl, aralkyl; R = (CH2)xX, O(CH2)xX, S(CH2)xX, NR1(CH2)xX; x = 0-3; X = H, alkyl, aryl, OH, alkoxy, acylamine, CON(R1)2, CO2R1, cyano, tetrazolyl; R3 = H, OH, alkoxy, halo, haloalkyl, CH2R, R, CH2O(CH2)xX; also (R)2 = (CH2)y with y = 1-4; RR1 = (CH2)z with z = 2-5; RR1 = CHR1; A = O, S, SO, SO2, NR1, CO, NR1CO, CONR1, CR1:CR1, bond; B = O, S, NR1, CR1:CR1, bond; a = 0-2, b = 0-2, (a + b) = 1-2; c, d = 0-3; n = 0-2; Z = CRR1Y, (un)substituted tetrazolyl; Y = CO2R1, cyano, CON(R1)2, CONHSO2R1, OR1] were prepd. as antiinflammatory and antiallergic agents (no data). Condensation of p-HOC6H4CHO with quinaldine in Ac2O, followed by deacetylation, gave 4-[z-(quinolin-2-yl)ethenyl]phenol, which underwent condensation with 2-(BrCH2)C6H4OCHMeCO2Et followed by basic hydrolysis to give quinoline deriv. II. Prepns. of several addnl. I are described.

IT **124993-46-0P 128760-03-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiinflammatory and antiallergic agent)

RN 124993-46-0 CAPLUS

CN Quinoline, 2-[2-[4-{[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 128760-03-2 CAPLUS
CN Propanoic acid, 2-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



L31 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:632595 CAPLUS
DOCUMENT NUMBER: 111:232595
TITLE: Preparation of quinoline derivatives as leukotriene D4 antagonists
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8904304	A1	19890518	WO 1988-US3896	19881101
W: AU, JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4920130	A	19900424	US 1987-116597	19871103
AU 8929114	A1	19890601	AU 1989-29114	19881101
AU 635199	B2	19930318		
EP 397697	A1	19901122	EP 1989-900969	19881101
EP 397697	B1	19960828		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500890	T2	19910228	JP 1989-500855	19881101
AT 141917	E	19960915	AT 1989-900969	19881101
US 5028615	A	19910702	US 1990-499513	19900420
US 5059610	A	19911022	US 1990-477896	19900420
US 5166210	A	19921124	US 1991-724745	19910702

PRIORITY APPLN. INFO.: US 1987-116597 19871103
WO 1988-US3896 19881101
WO 1988-US3897 19881101
US 1990-499513 19900420
OTHER SOURCE(S): MARPAT 111:232595

GI



I

II

AB The title compds. [I; A = O, S; B = CR1:CR1; D = bond, O, S, NR1, CR1:CR1; R1 = H, alkyl, aralkyl; R = H, alkyl, HO, alkoxy, carboxy, carbalkoxy, halo, O2N, haloalkyl, cyano, acyl; R2 = (CH2)xX; x = 0-3, X = H, alkyl, alkenyl, cycloalkyl, etc.; R3 = H, alkyl, OH, alkoxy, halo, haloalkyl; Z = CO2R1, cyano, CONHSO2R4, OR1, CONR12, (un)substituted tetrazolyl; R4 = H, alkyl, haloalkyl, Ph, PhCH2; a, c, n = 0-2; b = 0, 1; d = 0-3; e = 0-4; f = 0-5] were prepd. as leukotriene D4 inhibitors (no data). Thus, [Ph3PCH2C6H4CN-4]Cl was stirred 1 h with NaH in DMF after which 4-(R5CH2O)C6H4CHO (R5 = 2-quinolinyl) was added and the whole stirred 2 h to give 4-(R5CH2O)C6H4CH:CHC6H4CN-4 which was heated at 100.degree. for 48 h with NaN3 in DMF contg. pyridine-HCl to give the quinoline deriv. II.

IT **123791-11-7P 123791-12-8P 123791-15-1P**
123791-16-2P 123791-17-3P 123791-18-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as leukotriene D4 inhibitor)

RN 123791-11-7 CAPLUS

CN Quinoline, 2-[[4-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-12-8 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 123791-15-1 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-16-2 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 123791-17-3 CAPLUS
CN Quinoline, 2-[[3-[2-[4-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123791-18-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:632594 CAPLUS
DOCUMENT NUMBER: 111:232594

TITLE: Preparation of quinoline derivatives as leukotriene D4 antagonists
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8904303	A1	19890518	WO 1988-US3895	19881101
W: AU, JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4920133	A	19900424	US 1987-116428	19871103
AU 8827198	A1	19890601	AU 1988-27198	19881101
AU 635196	B2	19930318		
EP 395697	A1	19901107	EP 1988-910429	19881101
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500885	T2	19910228	JP 1988-509553	19881101
US 5051427	A	19910924	US 1990-449957	19900420
US 5059610	A	19911022	US 1990-477896	19900420

PRIORITY APPLN. INFO.: US 1987-116428 19871103
WO 1988-US3895 19881101
WO 1988-US3897 19881101
OTHER SOURCE(S): CASREACT 111:232594; MARPAT 111:232594
GI





I



II

AB Title compds. I [A = O, S; D = O, S, NR1, CR1:CR2, bond; E = bond, CR1:CR2; a, n = 0-2; b = 0.1; d = 1-5; e = 0-4; f = 0-5; R = H, alkyl, OH, alkoxy, CO2H, alkoxycarbonyl, halo, NO2 cyano, acyl, haloalkyl, R1 = H, alkyl, aralkyl; R2 = (CH2)xX; x = 0-3; X = H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, OH, alkoxy, mono- or dialkyl-, aralkyl-, or acyl-substituted)NH2, CONH2, CO2H, alkoxycarbonyl, tetrazolyl, acylsulfonamido; vicinal R2 groups = (CH2)y (y = 1-4) to form 3-6

membered ring; geminal R1 and R2 = (CH2)z (z = 2-5) to form spiro ring; geminal R1 or R1 and R2 = CHR1; Z = CO2R1, cyano, CONHSO2R4, CONR12, OR1, alkyl-, carboxyalkyl-, or alkoxycarbonylalkyl- substituted) tetrazolyl; R4 = H, alkyl, haloalkyl, Ph, PhCH2], are prepn. as the title antagonists and lipoxygenase inhibitors possessing antiinflammatory and antiallergic properties (no data). A quinoline II (Z = CONH2) (prepn. given) was heated with MeSO2Cl in pyridine at 70.degree. to give II (Z = cyano), which was treated with NaN3 in DMF in the presence of NH4Cl at 100.degree. to afford II (Z = 5-tetrazolyl).

IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Ar I

a=1 b=0 c/d=1 e,f=0
B is a bond
D,E bond



RN 123692-28-4 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 CAPLUS
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 CAPLUS
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 CAPLUS
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 CAPLUS
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:497460 CAPLUS
DOCUMENT NUMBER: 113:97460
TITLE: Preparation of quinoline derivatives useful as lipoxygenase inhibitors and/or leukotriene antagonists
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 348155	A1	19891227	EP 1989-306232	19890620
EP 348155	B1	19990512		
R: DE, ES, FR, GB, IT				
US 4920131	A	19900424	US 1988-209428	19880621
EP 784052	A1	19970716	EP 1997-200638	19890620
R: DE, ES, FR, GB, IT				
US 5059610	A	19911022	US 1990-477896	19900420

PRIORITY APPLN. INFO.:
US 1988-209428 19880621
US 1987-116420 19871103
US 1987-116428 19871103
US 1987-116597 19871103
WO 1988-US3897 19881101
EP 1989-306232 19890620

OTHER SOURCE(S): MARPAT 113:97460
GI



I



II

AB Title compds. I [A = O, S; B = bond, O, S, SO, SO2, NR1, CO, NR1CO, CONR1, CR1:CR1; D = O, S, NR1, CR1:CR1, bond; E = bond, CR1:CR1; a = 0-2; b = 0-1; c = 0-4; d = 0-5, e = 0-4; f = 0-5; n = 0-2; R2 = H, alkyl, OH, alkoxy, CO2H, carbalkoxy, halo NO2, haloalkyl, cyano, acyl; R3 = H, OH, alkoxy, halo, etc.; R1 = H, alkyl, aralkyl; R = (CH2)xX, O(CH2)xX, S(CH2)xX, NR1(CH2)xX; x = 0-3; X = H, alkyl, alkenyl, aryl, alkoxy, amino, cyano, tetrazolyl, CO2R, etc.; (R)2 = (CH2)y with y = 1-4; RR1 = (CH2)z with z = 2-5; (R1)2, RR1 = CHR1; Z = CO2R1, cyano, CONHSO2R4 with R4 = H, alkyl, Ph, etc.; CON(R1)2, OR1, (un)substituted tetrazolyl] were prepd. as antiinflammatory and antiallergic agents (no data). Thus, condensation of o-cresol with MeCHBr Co2Et and bromination of the product with NBS gave 2-(BrCH2)C6H4 OCHMeCO2Et, which underwent condensation with 3-(2-quinolinylmethoxy)phenol and basic hydrolysis to give quinoline deriv. II. Several addnl. prepns. and numerous I are given.

IT **120128-20-3P 123247-27-8P 128760-51-0P**
128760-53-2P 128760-54-3P 128760-55-4P
128760-56-5P 128760-57-6P 128760-59-8P
128760-60-1P 128760-61-2P 128760-62-3P
128760-69-0P 128760-73-6P 128760-74-7P
128760-75-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergic and antiinflammatory agent)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-27-8 CAPLUS

CN Pentanoic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-51-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-53-2 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-54-3 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 128760-55-4 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 128760-56-5 CAPLUS
CN Acetamide, 2-[4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-57-6 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 128760-59-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-60-1 CAPLUS
CN Propanoic acid, 2-[2-propyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-61-2 CAPLUS
CN Acetic acid, [4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-62-3 CAPLUS
CN Acetic acid, [4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-69-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-73-6 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-[(8-fluoro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 128760-74-7 CAPLUS
CN Quinoline, 8-fluoro-2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 128760-75-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-propyl-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:632596 CAPLUS
DOCUMENT NUMBER: 111:232596
TITLE: Quinoline derivatives, their use in the treatment of hypersensitive ailments, and pharmaceutical compositions containing them
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 315399	A2	19890510	EP 1988-310241	19881101
EP 315399	A3	19901128		

EP 315399	B1	19960110		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4920132	A	19900424	US 1987-116420	19871103
WO 8904305	A1	19890518	WO 1988-US3897	19881101
W: AU, JP, US				
AU 8927946	A1	19890601	AU 1989-27946	19881101
AU 633475	B2	19930204		
JP 03500889	T2	19910228	JP 1989-500520	19881101
JP 07107053	B4	19951115		
AT 132856	E	19960115	AT 1988-310241	19881101
US 5059610	A	19911022	US 1990-477896	19900420
PRIORITY APPLN. INFO.:			US 1987-116420	19871103
			WO 1988-US3897	19881101

OTHER SOURCE(S): CASREACT 111:232596; MARPAT 111:232596

GI



I



II

AB Quinolines I [A = O, S; B = O, S, SO, SO2, NR1, CO, NR1CO, CONR1; D = O, S, NR, CR1:CR1, bond; E = bond, CR1:CR1; a, n = 0-2; b = 0-1; c, e = 0-4; d, f = 0-5; R = H, alkyl, OH, alkoxy, CO2H, carbalkoxy, halo, NO2, haloalkyl, cyano, acyl; R' = H, alkyl, OH, alkoxy, halo, haloalkyl; R1 = H, alkyl, aralkyl; R2 = (CH2)xX; x = 0-3; X = H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, OH, alkoxy, aralkoxy, (di)(alkyl)amino, aralkylamino, acylamino, carbamyl, CO2H, carbalkoxy, tetrazolyl, acylsulfonamido; vicinal (R2)2 = (CH2)y; y = 1-4; geminal (R2)2 = (CH2)z; z = 2-5; geminal (R1)2, R1R2 = :CHR1; Z = CO2R1, cyano, CONHSO2R3, CON(R1)2, OR, tetrazolyl (may be substituted by alkyl, carboxyalkyl, or carbalkoxyalkyl); R3 = H, alkyl, haloalkyl, Ph, PhCH2] are prepd. as lipoxygenase inhibitors and/or leukotriene antagonists (no data). Alkylation of Na 3-(2-quinolinylmethoxy)phenoxide by p-NCC6H4CH2Br in DMF gave 4-[3-(2-quinolinylmethoxy)phenoxymethyl]benzonitrile, which underwent cycloaddn. with HN3 (from NaN3 and pyridine-HCl) in DMF to give title [[(quinolinylmethoxy)phenoxymethyl]phenyl]tetrazole II.

IT **120128-20-3P 123225-57-0P 123225-58-1P**
123225-59-2P 123225-60-5P 123225-64-9P
123225-66-1P 123225-67-2P 123225-69-4P
123225-71-8P 123225-73-0P 123225-75-2P
123225-76-3P 123225-78-5P 123225-80-9P

123225-81-0P 123225-82-1P 123225-94-5P
123225-95-6P 123225-96-7P 123225-97-8P
123225-98-9P 123225-99-0P 123226-00-6P
123226-01-7P 123226-03-9P 123226-04-0P
123226-05-1P 123226-07-3P 123226-08-4P
123226-09-5P 123226-11-9P 123226-13-1P
123226-14-2P 123226-15-3P 123226-16-4P
123226-17-5P 123226-18-6P 123226-19-7P
123226-20-0P 123226-21-1P 123226-22-2P
123226-23-3P 123226-24-4P 123226-25-5P
123226-26-6P 123226-27-7P 123247-23-4P
123247-24-5P 123247-25-6P 123247-27-8P
123247-28-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)

RN 120128-20-3 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-57-0 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-58-1 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-59-2 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-60-5 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-64-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-66-1 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-67-2 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-69-4 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methy

l]- (9CI) (CA INDEX NAME)



RN 123225-71-8 CAPLUS
CN Benzoic acid, 3-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-73-0 CAPLUS
CN Benzoic acid, 4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-3-(1H-tetrazol-5-ylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-75-2 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 123225-76-3 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-78-5 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-80-9 CAPLUS
CN Quinoline, 2-[[3-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-81-0 CAPLUS
CN Quinoline, 2-[[3-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-82-1 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-94-5 CAPLUS
CN Quinoline, 2-[[3-[[2-methoxy-5-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-95-6 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-96-7 CAPLUS
CN Quinoline, 2-[[4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-97-8 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123225-98-9 CAPLUS
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl

]- (9CI) (CA INDEX NAME)



RN 123225-99-0 CAPLUS
CN Acetic acid, [4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-00-6 CAPLUS
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123226-01-7 CAPLUS
CN Acetic acid, [4-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-03-9 CAPLUS
CN Propanoic acid, 2-[2-[[4-[(7-chloro-2-quinolinyl)methoxy]phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-04-0 CAPLUS
CN Acetic acid, [2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-05-1 CAPLUS
CN Acetic acid, [3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-07-3 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-08-4 CAPLUS
CN Acetic acid, [2-methyl-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-09-5 CAPLUS
CN Pentanedioic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-11-9 CAPLUS
CN Pentanoic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-13-1 CAPLUS
CN Pentanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-14-2 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-4-[[4-(2-quinolinylmethoxy)phenoxy]methyl
]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 123226-15-3 CAPLUS
CN Propanoic acid, 2-[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 123226-16-4 CAPLUS
CN Pentanedioic acid, 2-[2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-17-5 CAPLUS
CN Acetic acid, [2-[[3-(2-quinolinylmethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-18-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-19-7 CAPLUS
CN Propanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123226-20-0 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-21-1 CAPLUS
CN Pentanoic acid, 2-[4-chloro-2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-22-2 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-23-3 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]- (9CI) (CA INDEX NAME)



RN 123226-24-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-25-5 CAPLUS
CN Pentanoic acid, 2-[2-chloro-6-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phen oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 123226-26-6 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylsulfonyl)-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 123226-27-7 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-yl)phenoxy]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-23-4 CAPLUS
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-24-5 CAPLUS
CN Benzoic acid, 3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 123247-25-6 CAPLUS
CN Quinoline, 2-[[3-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123247-27-8 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(2-quinolinylmethoxy)phenoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 123247-28-9 CAPLUS
CN Acetic acid, [6-acetyl-2-propyl-3-[[3-(2-quinolinylmethoxy)phenyl]methoxy] phenoxy]- (9CI) (CA INDEX NAME)



L31 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:165766 CAPLUS
DOCUMENT NUMBER: 110:165766
TITLE: Antagonism of peptidoleukotrienes and inhibition of systemic anaphylaxis by RG 12525 in guinea pigs
AUTHOR(S): Van Inwegen, R. G.; Nuss, G. W.; Carnathan, G. W.
CORPORATE SOURCE: Dep. Immunol., Rorer Cent. Res., Horsham, PA, 19044, USA
SOURCE: Life Sciences (1989), 44(12), 799-807
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB RG 12525 (I) is a specific, competitive and orally effective antagonist of the peptidoleukotrienes LTC4, LTD4, and LTE4 in guinea pigs. In vitro, RG 12525 competitively inhibited [3H]LTD4 binding to lung membranes (Ki = 3.0 nM) and competitively antagonized the spasmogenic activity of LTC4, LTD4, and LTE4 on lung strips (KB = 3 nM) with >8000-fold selectivity. In vivo oral RG 12525 inhibited LTD4-induced wheal formation (ED50 = 5 mg/kg with a t1/2 = 10 h at 9 mg/kg), LTD4-induced bronchoconstriction (ED50 = 0.6 mg/kg), anaphylactic death (ED50 = 2.2 mg/kg with a t1/2 = 7 h at 10 mg/kg), and antigen-induced bronchoconstriction (ED50 = 0.6 mg/kg). RG 12525 has a strong receptor affinity and oral efficacy. It is a valuable pharmacol. tool to evaluate peptidoleukotrienes in allergic diseases.

IT **120128-20-3**, RG 12525
RL: BIOL (Biological study)
(leukotrienes inhibition by, in anaphylaxis)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:433309 CAPLUS
DOCUMENT NUMBER: 111:33309
TITLE: The effect of RG 12525 on leukotriene D4-mediated pulmonary responses in guinea pigs
AUTHOR(S): Carnathan, G. W.; Sweeney, D.; Travis, J.; Van Inwegen, R. G.
CORPORATE SOURCE: Dep. Immunol., Rorer Cent. Res., Horsham, PA, 19044, USA
SOURCE: Agents and Actions (1989), 27(3-4), 316-18
CODEN: AGACBH; ISSN: 0065-4299
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB RG 12525 (I) is under investigation as a specific inhibitor of leukotriene D4 (LTD4). The effect of orally administered RG 12525 was studied on LTD4 mediated pulmonary responses in 3 sep. guinea pig models. The compd. inhibited antigen-induced mortality in the systemic anaphylaxis model with

an ED50 (95% confidence interval) = 2.2 (0.8-6.4) mg/kg. In this model, the activity half-life of RG 12525 was 6.5 h and the compd. offered significant protection within 15 min of administration. RG 12525 also protected against LTD4-induced bronchoconstriction in a model measuring changes in pulmonary function with an ED50 = 0.6 (0.4-1.0) mg/kg. The same level of activity was obsd. in a similar model which monitored changes in pulmonary function in response to exogenous antigen in actively-sensitized guinea pigs. Thus, RG 12525 is a potent, orally active LTD4 antagonist which possesses the requisite profile for potential clin. development.

IT **120128-20-3**, RG 12525
RL: BIOL (Biological study)
(leukotriene D4 antagonism by)

RN 120128-20-3 CAPLUS

CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 29 OF 38 USPATFULL

ACCESSION NUMBER:	2002:228358 USPATFULL
TITLE:	Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
INVENTOR(S):	Marfat, Anthony, Mystic, CT, UNITED STATES McKechney, Michael William, Fairport, NY, UNITED STATES
PATENT ASSIGNEE(S):	Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002123520	A1	20020905	
APPLICATION INFO.:	US 2002-62145	A1	20020131	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265486P	20010131 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	6963

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: ##STR1##

where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, 2, or 3; n is 1 or 2; W.sup.1 is --O--; or --S(.dbd.O)t--, where t is 0, 1, or 2; or --N(R.sup.3)--; W.sup.2 is --CR.sup.AR.sup.B or is absent; Y is .dbd.C(R.sup.1.sub.a)-- or --[N(O).sub.k]-- where k is 0 or 1; R.sup.A and R.sup.B are --H; --F; --CF.sub.3;

--(C.sub.1-C.sub.4) alkyl; --(C.sub.3-C.sub.7) cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R.sup.10; or R.sup.A and R.sup.B are taken together, but only in the case where m is 1, to form a spiro moiety; R.sup.C and R.sup.D have the same meaning as R.sup.A and R.sup.B except that one of them must be --H, R.sup.1 and R.sup.2 are --H; --F; --Cl; --CN; --N O.sub.2; --(C.sub.1-C.sub.4) alkyl; --(C.sub.2-C.sub.4) alkynyl; fluorinated --(C.sub.1-C.sub.3) alkyl; --OR.sup.16; and --C(.dbd.O)NR.sup.22.sub.aR.sup.22.sub.b; R.sup.3 is --H; --(C.sub.1-C.sub.3) alkyl; phenyl; benzyl; or --OR.sup.16; R.sup.4, R.sup.5 and R.sup.6 in addition to other meanings may be taken together to form, e.g., ##STR2##

G.sup.1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G.sup.1 is not a discontinuous or restricted biaryl moiety as defined under G.sup.2; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; --G.sup.2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted biaryl moiety; wherein for each of the carbon ring systems recited, optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; and E is selected from: ##STR3##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120128-20-3**, RG-12525
(combination therapy with PDE4 inhibitors; prepn. of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid amide derivs. as inhibitors of PDE4 isoenzymes)
RN 120128-20-3 USPATFULL
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 30 OF 38 USPATFULL
ACCESSION NUMBER: 93:56920 USPATFULL
TITLE: Combination of PAF antagonists and LTD.sub.4 antagonists for the treatment of allergic reactions
INVENTOR(S): O'Donnell, Margaret, Clifton, NJ, United States
Welton, Ann, North Caldwell, NJ, United States
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5227378		19930713
APPLICATION INFO.:	US 1992-848564		19920309 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-561743, filed on 2 Aug

1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, S. J.
LEGAL REPRESENTATIVE: Gould, George M., Johnston, George W., Krovatin, William
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions comprising combinations of a PAF antagonist and a LTD.sub.4 antagonist which combinations synergistically provide protection against allergic reactions such as antigen-induced death in mammals.

In another aspect, the invention relates to the use of the referred to combinations in the treatment of allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120128-20-3D**, mixts. with platelet-activating factor antagonists (antiallergic compns. contg.)
RN 120128-20-3 USPATFULL
CN Quinoline, 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 31 OF 38 USPATFULL
ACCESSION NUMBER: 92:92818 USPATFULL
TITLE: Quinoline derivatives as antagonists of leukotriene D4
INVENTOR(S): Huang, Fu-Chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5166210		19921124
APPLICATION INFO.:	US 1991-724745		19910702 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-499513, filed on 20 Apr 1990, now patented, Pat. No. US 5028615, issued on 2 Jul 1991 which is a continuation-in-part of Ser. No. US 1987-116597, filed on 3 Nov 1987, now patented, Pat. No. US 4920130, issued on 24 Apr 1990
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Synnestvedt & Lechner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Quinolinyl styryl compounds and their use as pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 USPATFULL

CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL

CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL

CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL

CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL

CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 32 OF 38 USPATFULL
ACCESSION NUMBER: 91:86750 USPATFULL

TITLE: Quinoline derivatives and their use as antagonists of leukotriene D.sub.4
INVENTOR(S): Huang, Fu-Chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Fort Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5059610		19911022	
	WO 8904305		19890518	
APPLICATION INFO.:	US 1990-477896		19900420	(7)
	WO 1988-US3897		19881101	
			19900420	PCT 371 date
			19900420	PCT 102(e) date

DISCLAIMER DATE: 20070424
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Savitzky, Martin F., Nicholson, James A., Barron, Alexis
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1,42
LINE COUNT: 1874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to quinolinyl-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)
RN 123692-25-1 USPATFULL
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 33 OF 38 USPATFULL

ACCESSION NUMBER:	91:77771 USPATFULL
TITLE:	Quinoline derivatives as antagonists of leukotriene D.sub.4
INVENTOR(S):	Huang, Fu-Chi, Gwynedd, PA, United States Galemmo, Jr., Robert A., Ambler, PA, United States Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S):	Rhone-Poulenc Rorer Pharmaceuticals Inc., Fort Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5051427		19910924	
	WO 8904303		19890518	
APPLICATION INFO.:	US 1990-449957		19900420	(7)
	WO 1988-US3895		19881101	
			19900420	PCT 371 date
			19900420	PCT 102(e) date

DISCLAIMER DATE:	20070417
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-116428, filed on 3 Nov 1987, now patented, Pat. No. US 4920133, issued on 24 Apr 1990
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Springer, David B.
LEGAL REPRESENTATIVE:	Savitsky, Martin F., Nicholson, James A., Barron, Alexis
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	1,21
LINE COUNT:	1116

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **123692-25-1P 123692-28-4P 123692-29-5P 123692-36-4P 123692-37-5P 123692-38-6P 123692-39-7P 123692-40-0P 123715-60-6P**

(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 USPATFULL

CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL

CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL

CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL

CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL

CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 34 OF 38 USPATFULL
ACCESSION NUMBER: 91:52554 USPATFULL
TITLE: Quinoline derivatives as antagonists of leukotriene D4
INVENTOR(S): Huang, Fu-Chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Fort Washington, PA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:	US 5028615	19910702	
	WO 8904304	19890518	
APPLICATION INFO.:	US 1990-499513	19900420	(7)
	WO 1988-US3896	19881101	
		19900420	PCT 371 date
		19900420	PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Springer, David B.		
LEGAL REPRESENTATIVE:	Savitzky, Martin F., Nicholson, James A., Barron, Alexis		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	894		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 USPATFULL

CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL

CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL

CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 35 OF 38 USPATFULL
ACCESSION NUMBER: 90:32220 USPATFULL
TITLE: Quinoline derivatives and use thereof as antagonists of leukotriene D.sub.4
INVENTOR(S): Huang, Fu-chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rorer Pharmaceutical Corp., Fort Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4920133		19900424
APPLICATION INFO.:	US 1987-116428		19871103 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Nicholson, James A., Savitzky, Martin, Balogh, Imre J.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 1174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)
RN 123692-25-1 USPATFULL
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 36 OF 38 USPATFULL
ACCESSION NUMBER: 90:32219 USPATFULL
TITLE: Quinoline derivatives and use thereof as antagonists of leukotriene D.sub.4
INVENTOR(S): Huang, Fu-chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rorer Pharmaceutical Corp., Ft. Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4920132		19900424
APPLICATION INFO.:	US 1987-116420		19871103 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Nicholson, James A., Savitzky, Martin, Balogh, Imre Jim
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1,41
LINE COUNT: 1683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 USPATFULL
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 37 OF 38 USPATFULL
ACCESSION NUMBER: 90:32217 USPATFULL
TITLE: Quinoline derivatives and use thereof as antagonists of

leukotriene D.sub.4

INVENTOR(S): Huang, Fu-chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States

PATENT ASSIGNEE(S): Rorer Pharamceutical Corp., Fort Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4920130		19900424
APPLICATION INFO.:	US 1987-116597		19871103 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Nicholson, James A., Savitzky, Martin, Balogh, Imre Jim
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1,21
LINE COUNT: 836
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **123692-25-1P 123692-28-4P 123692-29-5P**
123692-36-4P 123692-37-5P 123692-38-6P
123692-39-7P 123692-40-0P 123715-60-6P
(prepn. of, as leukotriene antagonist and lipoxygenase inhibitor)

RN 123692-25-1 USPATFULL
CN Quinoline, 2-[[4-[[4-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-28-4 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-29-5 USPATFULL
CN Quinoline, 2-[[4-[[3-(1H-tetrazol-5-yl)phenyl]methyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-36-4 USPATFULL
CN Quinoline, 2-[[3-[2-[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-37-5 USPATFULL
CN Benzeneacetic acid, 2-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 123692-38-6 USPATFULL
CN Benzeneacetic acid, 2-[[4-(2-quinolinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 123692-39-7 USPATFULL
CN Quinoline, 2-[[4-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123692-40-0 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-ylmethyl)phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 123715-60-6 USPATFULL
CN Quinoline, 2-[[3-[2-[3-(1H-tetrazol-5-yl)phenyl]propyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 38 OF 38 USPATFULL
ACCESSION NUMBER: 90:30025 USPATFULL
TITLE: Quinoline derivatives and use thereof as antagonists of leukotriene d4
INVENTOR(S): Huang, Fu-Chi, Gwynedd, PA, United States
Galemmo, Jr., Robert A., Ambler, PA, United States
Campbell, Henry F., North Wales, PA, United States
PATENT ASSIGNEE(S): Rorer Pharmaceutical Corp., Ft. Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4918081		19900417
APPLICATION INFO.:	US 1988-210468		19880620 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Nicholson, James A., Imre, Martin S., Balogh, Jim
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,15
LINE COUNT: 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to quinolinyl compounds of the general formula: ##STR1## and the use of these compounds as pharmacological agents which are lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties and their pharmaceutical compositions and processes for this preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **124993-46-0P 128760-03-2P**
(prepn. of, as antiinflammatory and antiallergic agent)
RN 124993-46-0 USPATFULL
CN Quinoline, 2-[2-[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 128760-03-2 USPATFULL
CN Propanoic acid, 2-[2-[[4-[2-(2-quinolinyl)ethenyl]phenoxy]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 17:01:05 ON 28 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L18 620 SEA FILE=REGISTRY ABB=ON (100-83-4/BI OR 1008-88-4/BI OR 1011-50-3/BI OR 102-47-6/BI OR 103-74-2/BI OR 10340-77-9/BI OR 103788-61-0/BI OR 103788-64-3/BI OR 103788-65-4/BI OR 104-83-6/BI OR 104-90-5/BI OR 10447-76-4/BI OR 105-36-2/BI OR 105983-77-5/BI OR 106435-53-4/BI OR 107432-15-5/BI OR 1078-28-0/BI OR 107813-58-1/BI OR 108-46-3/BI OR 108325-70-8/BI OR 1122-56-1/BI OR 1123-63-3/BI OR 1128-61-6/BI OR 118-48-9/BI OR 118-75-2/BI OR 119-36-8/BI OR 120-50-3/BI OR 120-72-9/BI OR 1201-68-9/BI OR 120128-20-3/BI OR 123225-57-0/BI OR 123225-58-1/BI OR 123225-59-2/BI OR 123225-60-5/BI OR 123225-64-9/BI OR 123225-66-1/BI OR 123225-67-2/BI OR 123225-69-4/BI OR 123225-71-8/BI OR 123225-73-0/BI OR 123225-75-2/BI OR 123225-76-3/BI OR 123225-78-5/BI OR 123225-80-9/BI OR 123225-81-0/BI OR 123225-82-1/BI OR 123225-94-5/BI OR 123225-95-6/BI OR 123225-96-7/BI OR 123225-97

-8/BI OR 123225-98-9/BI OR 123225-99-0/BI OR 123226-00-6/BI OR 123226-01-7/BI OR 123226-03-9/BI OR 123226-04-0/BI OR 123226-05-1/BI OR 123226-07-3/BI OR 123226-08-4/BI OR 123226-09-5/BI OR 123226-11-9/BI OR 123226-13-1/BI OR 123226-14-2/BI OR 123226-15-3/BI OR 123226-16-4/BI OR 123226-17-5/BI OR 123226-18-6/BI OR 123226-19-7/BI OR 123226-20-0/BI OR 123226-21-1/BI OR 123226-22-2/BI OR 123226-23-3/BI OR 123226-24-4/BI OR 123226-25-5/BI OR 123226-26-6/BI OR 123226-27-7/BI OR 123226-28-8/BI OR 123226-29-9/BI OR 123247-23-4/BI OR 123247-24-5/BI OR 123247-25-6/BI OR 123247-27-8/BI OR 123247-28-9/BI OR 123692-25-1/BI OR 123692-28-4/BI OR 123692-29-5/BI OR 123692-36-4/BI OR 123692-37-5/BI OR 123692-38-6/BI OR 123692-39-7/BI OR 123692-40-0/BI OR 123715-60-6/BI OR 123791-11-7/BI OR 123791-12-8/BI OR 123791-15-1/BI OR 123791-16-2/BI OR 123791-17-3/BI OR 123791-18-4/BI OR 124993-46-0/BI OR 128760-03-2/BI OR 128760-38-3/BI OR 128760

L22 STR

L25 389 SEA FILE=REGISTRY SUB=L18 SSS FUL L22

L30 0 SEA FILE=CAOLD ABB=ON L25

FILE 'HOME' ENTERED AT 17:01:05 ON 28 OCT 2002